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1.1 Summary 
 
Double strand breaks (DSBs) are one of the most dangerous forms of DNA damage. 
A globular cellular response is activated upon induction of DSBs. Mediator of DNA 
damage checkpoint 1 (MDC1) is one of those proteins involved in the DNA damage 
response (DDR) that contains an N-terminal forkhead associated (FHA) domain and a 
tandem BRCA1 C-terminal (BRCT) domain. MDC1 is recruited to sites of DNA 
damage upon phosphorylation of variant histone 2A (H2AX) by the kinase ataxia 
telangiectasia mutated (ATM).  
In order to identify the amino acids that are targeted by ATM, we took a candidate 
approach and mutated a Threonine residue at the N-terminus of MDC1 to Alanin. We 
then performed an ATM kinase assay using radioactive ATP in order to check 
whether the T4A mutant fragment was still phosphorylated by ATM. Results of this 
study clearly revealed that ATM phosphorylates Thr 4 in MDC1 in vitro. We suggest 
that Thr4 is the major ATM phosphorylation site within the N-terminus of MDC1.   
In a second part of this work, we sought to develop a proteomics approach to identify 
novel components of the DDR. We set up a tandem affinity purification (TAP) 
system using the BRCA1-BRCT domains fused to enhanced yellow fluorescent 
protein (EYFP) and triple-tagged at the C-terminus by a Streptavidin-binding peptide 
(Strep-tag II) a Flag-tag and an S-tag. As the Strep-tag II did not efficiently bind to 
Streptavidin, the performance of a TAP was not successful. 
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1.2 Zusammenfassung 
 
DNS Doppelstrangbrüche (DSB) gehören zu den gefährlichsten DNS Schäden und 
führen zu einer weitgreifenden zellulären Antwort. Mediator of DNA damage 
checkpoint 1 (MDC1) ist ein Protein dieser DNA damage response (DDR) und besitzt 
eine N-terminale FHA als auch eine C-terminale tandem BRCT Domäne. MDC1 wird 
als Folge der Phosphorylierung von variant Histone 2A (H2AX) durch die Kinase 
Ataxia Telangiectasia mutated (ATM) zum Ort eines DNS Schadens rekrutiert.  
Um die von ATM phosphorylierte Aminosäure zu identifizieren, wurde Thr4 als 
potentieller Kandidat zu Ala ummutiert. Mit radioaktivem ATP wurde ein ATM-
Kinase Assay durchgeführt um herauszufinden ob das T4A mutierte Fragment immer 
noch phosphoryliert wird. Die Ergebnisse zeigten, dass T4A von ATM in vitro 
phosphoryliert wird. Folglich ist T4 die einzige ATM Phosphorylierungsstelle am N-
Terminus von MDC1. 
In einem zweiten Teil entschieden wir uns ein Proteomicsverfahren zu etablieren um 
neue Komponenten der DDR zu identifizieren. Wir entwickelten eine Tandem 
Affinity Purification (TAP), bestehend aus der BRCA1 BRCT Domäne verbunden 
mit dem enhanced yellow fluorescent protein (EYFP) und einem Trippel-tag am C-
Terminus gebildet von einem Streptavidin-bindenden Peptid (Strep-tag II), einem 
Flag-tag und einem S-tag. Da der Strep-tag II nicht effizient von Streptavidin 
gebunden wurde, blieb die Durchführung der TAP erfolglos. 
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2. Introduction 
 
The human genome exists of 3 billion base pairs and forms a sensitive unity in 
combination with various proteins localized in the cell nucleus. The maintenance of 
the genetic code is of prime importance; small alterations can cause serious 
consequences. A single mutation can already lead to severe developmental disorder or 
cancer formation. Our genome is in permanent danger from unavoidable DNA-
damaging agents like ultraviolet light, ionizing radiation or genotoxic agents, which 
induce such mutations if left unrepaired. However, not only environment endangers 
genomic integrity but also byproducts of our normal cell cycle cause numerous forms 
of damage. Attention is focused on reactive oxygen species (ROS), which accumulate 
from oxygen respiration or as products of lipid peroxydation (Hoeijmakers et al., 
2001).  
In general, cancer formation is promoted when critical genes are mutated (Vogelstein 
et al., 2004). There are two major factors that affect mutation rate; exposure to 
carcinogens as already mentioned but also efficiency of cellular pathways that 
process DNA damage (Paz-Elizur et al., 2006). This process comprises the faultless 
execution of genome surveillance pathways that detect, signal and repair DNA 
damage and thereby coordinate cell cycle progression to ensure correct DNA 
replication and gene expression.  Mutations or chromosomal aberrations caused by 
unrepaired or incorrectly repaired DNA damage can also lead to cell apoptosis, 
immunodeficiency, premature aging and neurodegeneration (Stucki, Clapperton et al., 
2005). 
DNA can be damaged in various forms. However, DNA double strand breaks (DSBs) 
are of special interest because of their enormous reparation investigations resulting in 
a high mutation risk. Thus, DSBs represent one of the most difficult kinds of damage 
to be repaired accurately. A double strand break occurs when both strands of the 
DNA double helix rupture and complementary overhangs cannot keep DNA ends 
juxtaposed just by base pairing, so that they dissociate from each other. DSBs not 
only arise from ionizing radiation or radiomimetic chemicals but also from mechanic 
stress on chromosomes, as products of collapsed replication forks or even from a 
physiological event during V(D)J recombination in developing B- and T-lymphocytes 
to achieve antigen binding diversity (Jackson 2002).  
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2.1. DNA Double Strand Breaks 
 
2.1.1. DSB repair mechanisms 
 
Due to their importance for all forms of life, DSB repair mechanisms are highly 
conserved through out evolution and can be found in phages, bacteria, yeast and 
higher eukaryotes (Cromie et al., 2001). There are two main repair pathways for 
DSBs; homologues recombination (HR) and non-homologues end joining (NHEJ). 
These two pathways differ in their occurrence during cell cycle. In mammalian cells 
the NHEJ repair mechanism prevails particularly in G0- and G1- phase, whereas HR 
predominates mainly in S- and G2-phase when the undamaged sister chromatid can 
be used as a template (Shrivastav et al., 2008).  
 
2.1.2. Non-homologous end joining 
 
Although NHEJ works not as accurately as HR it is the predominant repair 
mechanism in higher eukaryotes. When no sister chromatid is present free DNA ends 
are directly joined often by adding or deleting nucleotides (Budman et al., 2005). In 
mammalian cells NHEJ is used to repair DNA DSBs and to join gene segments 
during V(D)J-recombination in developing lymphocytes. The DNA dependent protein 
kinase (DNA-PK) plays a central role in NHEJ and is activated upon association with 
DNA. DNA-PK is a serine-threonine kinase consisting of a DNA binding subunit and 
a catalytic component (Smith and Jackson et al., 1999). The Ku protein representing 
the DNA binding subunit is a heterodimer of 70 and 86 kDa that binds to DNA ends, 
nicks and structures containing a transition fork between double-stranded DNA and 
two single strands. The Ku protein makes no contacts with DNA bases and only few 
with the sugar-phosphate backbone so that DNA end interactions are structure and 
sequence-independent. The crystal structure of the Ku70-Ku80 complex reveals a 
central domain forming a double ring that encircles the DNA molecule (Riha et al., 
2006). Ku and the DNA-PK catalytic subunit (DNA-PKcs) show only weak 
association in the absence of free DNA ends. However, when the Ku heterodimer 
binds to DNA ends, the Ku80 subunit changes its conformation and a 12-amino acid 
sequence from the C terminus becomes exposed. This sequence specifically binds and 
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recruits the 465kDa DNA-PKcs to the DNA end. DNA-PKcs contains a separate 
DNA binding domain that binds DNA ends with much lower affinity and specificity 
as compared to Ku (Martensson et al., 2002). Sequence analysis of the catalytic 
domains revealed DNA-PKcs to be a member of the phosphatidylinositol 3-kinase-
like family (PIKK) that also includes ATM (ataxia telangiectasia mutated) and ATR 
(ATM related) (Hartley et al., 1995). Further studies have shown that a single 
stranded DNA end derived from a DSB is essential for DNA-PKcs activation 
(Hammarsten et al., 2000). DNA-PKcs also recruits and forms a complex with 
Artemis. DNA-Pkcs activates Artemis by phosphorylation and shows endonuclease 
hairpin opening activity (Ma et al., 2002), (Riha et al., 2006). Lack or mutations of 
DNA-PK subunits can lead to radio hypersensitivity or severe combined 
immunodeficiency.  
Although there are four DNA ligases expressed in mammalian cells encoded by three 
different genes, only Ligase 4 (Lig4) is involved in NHEJ. Lig 4 forms a 1:2 complex 
with the DNA repair factor XRCC4, which is necessary for ligase activity. The 
Lig4/XRCC4 complex has a unique single-strand ligation activity that permits joining 
of only one strand with the opposite strand (Grawunder et al., 1998), (Riha et al., 
2006). If DNA ends are compatible the ligation occurs immediately. If not, Artemis 
processes DNA ends until the Lig4/XRCC4 complex is capable to ligate them. DNA 
ends can also be resected by the MRN-complex, which harbors exo- and 
endonuclease activity as well as helicase and adenylat kinase activity. Finally, 
polymerases terminate NHEJ by filling the gaps, before Lig4/XRCC4 completes the 
joining reaction (Ma 2002) (see Figure 1). 
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Figure 1; Non-homologous end joining mechanism in DNA double-strand break repair  
(Adapted from Budman et al., EMBO journal, 2005) 
Ku heterodimer binds to DSB and targets DNA-PKcs to DNA. Together, Ku and DNA-PKcs form the 
catalytically active DNA-PK holoenzyme. Then, Ku recruits ligase 4 along with XRCC1 and DNA-
PK-dependent phosphorylation of XRCC1 influences its activity. Ligation process occurs immediately, 
if the DNA ends are compatible. Otherwise polymerase and nuclease activities process DNA ends into 
compatible substrates so that ligase 4/XRCC1 complex can complete the joining process. 
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2.2. Cellular responses to DNA double-strand breaks 
 
The induction of DSBs not only leads to activation of the repair pathways but also to 
globular cellular respone that inclutes regulation of cell cycle transitions, 
transcriptional activation and apoptosis. The cellular response to DSBs starts with the 
detection of the DNA lesion by sensory proteins, which trigger the activation of 
kinase-dependent signaling cascades. This so called DNA damage response (DDR) is 
a classical signal-transduction pathway consisting of sensors, transducers and 
effectors. In order for a single DSB to induce a cell cycle arrest, the initial signal must 
be amplified and diversified to a series of downstream effectors that control diverse 
cellular functions (Khanna et al., 2001).  
A conserved signaling component with a central role in cellular response to DSBs is 
ATM (ataxia telangiectasia mutated). The physiological importance of ATM is 
demonstrated in patients suffering from ataxia telangiectasia. Patients carrying two 
mutated ATM alleles exhibit progressive cerebellar ataxia, immune deficiencies, 
gonadal atrophy, oculocutaneous telangiectasias, radiation sensitivity, premature 
ageing and increased risk of cancers, particularly lymphomas (Bakkenist et al., 2003). 
The ATM gene encodes a 370-kDa protein that belongs to the phosphatidylinositol 3-
kinase-like (PIKK) family. In undamaged cells ATM exists as a homodimer, hiding 
the 350 amino acid kinase domain at the carboxy terminus. ATM gets recruited to 
DNA DSBs through the MRN complex, which consists of MRE11, RAD50 and 
NBS1 (Stucki et al., 2004), (Falck et al., 2005). MRN is among the first proteins that 
accumulate at sites of DSB in eukaryotic cells. NBS1 containing a FHA and BRCT 
domains and acts as a crucial mediator and adaptor in the DDR. Mutations in the 
NBS1 gene lead to Nijmegen breakage syndrome (NBS) in humans, and cells derived 
from NBS patients display a DSB repair defect and DNA damage signaling 
deficiencies. MRE11 is a structure-specific nuclease involved in DNA-end 
processing, while RAD50 displays ATPase and adenylate kinase activity (D’Amours 
et al., 2002), (Stracker et al., 2004), (Jazayeri et al., 2006), (Costanzo et al., 2004). 
Activation of the MRN complex leads to ATM auto-phosphorylation on multiple 
residues and the ATM dimers dissociate to active monomers which phosphorylate a 
variety of target proteins such as checkpoint kinase 2 (CHK2), mediator of DNA 
damage checkpoint 1 (MDC1), p53 binding protein 1 (53BP1), breast cancer 
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susceptibility protein (BRCA1) and histone 2A variant (H2AX). These 
phosphorylation events do not only target downstream factors regulating the repair 
pathways, they can also lead to transient or permanent cell cycle arrest if the damage 
persists, or to programmed cell death when DNA damage is too extensive. 
Phosphorylation of H2AX on Ser139 by ATM at sites of DNA damage leads to 
recruitment of MDC1, an important mediator protein. MDC1 acts to amplify H2AX 
phosphorylation, possibly by recruiting ATM into the DSB-flanking chromatin 
compartment or by preventing H2AX dephosphorylation (Stucki et al., 2006). Our lab 
established a model proposing that MRN and MDC1 exist as a complex whereby 
MDC1 mediates the recruitment of MRN to H2AX-containing chromatin (Spycher 
et al., 2008) (Kobayashi et al., 2002). MDC1 and phosphorylated H2AX allow the 
recruitment of many additional factors, that form the so-called DNA damage foci. 
One of those factors is 53BP1, a mediator that plays a role in CHK2 and p53 
activation (Harper et al., 2007). How 53BP1 gets recruited is still not entirely clear. 
MDC1 recruits Ubc13-Rnf8, an E3 ubiquitin ligase complex that ubiquitinylates H2A 
and H2AX and possibly other factors at sites of DSBs. 53BP1 and BRCA1 
recruitment seem to depend on this poly-ubiquitination (Huen et al., 2007), (Kolas et 
al., 2007), (Mailand et al., 2007), (Wang et al., 2007).  BRCA1 that is also recruited 
into DNA damage foci appears to have also a direct or indirect role in transcriptional 
activation as a component of the RNA polymerase II holoenzyme (Monterio et al., 
1996), (Chapman et al., 1996). BRCA1 contains, just like RNF8 a RING-finger 
domain and was observed to have E3 ubiquitin ligase activity that might be relevant 
in signal transduction (Baer et al., 2002). Recent studies revealed BRCA1 itself, H2A 
and H2AX and p53 as potential candidate substrates (Chen et al., 2002), (Vandenberg 
et al., 2003), (Billack et al., 2004).  
Effector proteins are either direct targets of ATM or are phosphorylated by the two 
checkpoint transducer kinases CHK1 and CHK2. The tumor suppressor p53 is one of 
the major effector proteins and is known to be mutated in many cancer cells. Once 
activated, it acts as a transcription factor regulating for example the expression of 
p21, a Cdk inhibitor protein responsible for G1 cell cycle arrest. Further on, the 
accumulation of p53 provokes apoptosis by activating the caspase-signaling cascade. 
In addition, Cdc25 phosphatase is another important effector of the DDR that controls 
cell cycle progression through regulation of cycline dependent kinases (CDKs) (Zhou 
2000) (see Figure 2).  
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Figure 2; Overview of the DNA damage response signal-transduction pathway 
(Adapted from Zhou and Elledge, Nature, 2000) 
Exposure of DNA to various agents lead to DNA damages that are recognized by multiple sensor 
proteins. This results in the activation of proximal kinases that trigger the activation of transducer 
proteins. Protein kinase cascades amplify and diversify the DNA damage signal and activate multiple 
downstream effector proteins that regulate different aspects of cellular function. Adaptor proteins 
influence coordination of DNA repair and are also important for signal amplification.  
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2.3. MDC1 
 
A key regulator of ionizing radiation induced foci (IRIF) formation in mammalian 
cells is histone variant H2AX, a component of the nucleosome core structure. H2AX 
comprises 10-15% of total cellular H2A in higher organisms and becomes rapidly 
phosphorylated on a C-terminal Ser residue (Ser139) in response to DNA damage. 
This phosphorylation is PIKK-dependent. In the past few years, research has focused 
on finding interaction partners for phosphorylated H2AX (termed H2AX). One of 
those discovered proteins that recognize and interact with phosphorylated H2AX is 
Mediator of DNA damage checkpoint 1 (MDC1). Interestingly, SDS-PAGE analysis 
revealed MDC1 to exist in three isoforms probably due to alternative splicing. MDC1 
contains two phosphorylation-specific interaction domains: a tandem breast cancer 
associated carboxy-terminal (BRCT) domain at the C-terminus and a forkhead 
associated (FHA) domain at its N-terminus (see Figure 3). Additionally, a large S/TQ 
cluster domain can be found encompassing the N-terminal part of the protein. S/TQ 
cluster domains (also present in BRCA1 and ChK2) are phosphorylated by ATM in 
response to DNA damage. Further domain analysis of MDC1 revealed a large central 
proline/serine/threonine-rich (PST) repeat domain that has no significant homology to 
any other protein (Stewart et al., 2003). MDC1 is not only claimed to be a mediator of 
damage checkpoint but also a mediator of damage repair since cells deficient in 
MDC1 display defects in DSB repair by HR (Xie et al., 2007) and NHEJ (Lou et al., 
2004). MDC1 shows dispersed localization in nuclei of undamaged cells whereas -
irradiation leads to accumulation at sites of DSBs that appears in fluorescence 
microscopy as bright nuclear foci that colocalize with H2AX foci. Cells lacking 
MDC1 are sensitive to ionizing radiation, disabled in foci formation and fail to 
activate the intra-S phase and G2/M phase cell cycle checkpoints properly after 
exposure to ionizing radiation, indicating that it is an important player in the cellular 
response to DSBs. 
Biochemical and structural analysis recently revealed that the tandem BRCT domain 
of MDC1 directly interacts with phosphorylated Ser139 residue of H2AX in a tight 
and highly specific manner (Stucki et al., 2005). This interaction is essential for 
MDC1’s relocalization in IRIF upon irradiation and abrogation of this interaction 
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triggers similar effects as loss of MDC1, indicating that it is functionally relevant. In 
addition to the C-terminal BRCT domains, MDC1 also features an FHA domain at its 
N-terminus. The MDC1 FHA domain recognizes phosphorylated threonine residues 
and recent study suggested MDC1 to play an essential role in the signal transduction 
of the ATM-p53 pathway that regulates apoptosis. In this study, it was reported that 
MDC1 associates with the ATM-phosphorylated protein kinase ChK2 through its 
FHA domain (Lou et al., 2003). Since a putative MDC1 FHA recognition sites has 
recently been discovered in MDC1 itself by our laboratory (Jungmichel et al. personal 
communication), further investigations were necessary to confirm that this putative 
FHA recognition site located at the N-terminus of MDC1 is indeed targeted by the 
ATM kinase (see results). 
 
 
 
 
Figure 3; Schematic overview of MDC1 domains 
MDC1 consists of 2089 amino acids and harbors several domains involved in protein interactions. The 
N-terminal FHA domain plays a crucial role in recognition of phosphorylated serine/threonine motifs. 
It was also shown that MDC1 interacts via its BRCT domain with phosphorylated H2AX at Ser139.  
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2.4. BRCA1 
 
The tumor suppressor gene encoding breast cancer 1 susceptibility protein (BRCA1) 
was among the first discovered genes bearing a hereditary predisposition for the 
development of breast and ovarian cancer. The BRCA1 gene is mutated in 8.5% of all 
breast cancer cases and over 450 mutations have been identified (Hemminki et al., 
2004). Whereas the lifetime risk of developing breast (45-87%) or ovarian (37-66%) 
cancer with inherited BRCA1 mutations is high, the risk of cancer in other tissues is 
small. Hormonal interference between BRCA1 and estrogen is a possible explanation 
for this tissue specificity as BRCA1 is reported to bind and inhibit the action of the 
estrogen-receptor. The importance of BRCA1 in the DDR is revealed by the fact that 
BRCA1 deficiency is compromising homologues recombination, transcription-
coupled repair, micro-homology end joining and NHEJ (Billack et al., 2005).   
BRCA1 consists of an amino terminal RING (really interesting new gene) -finger 
domain, a centrally located nuclear localization signal (NLS) and a C-terminal 
tandem BRCT domain (see Figure 4). Initially, the presence of these domains led to 
the hypothesis that BRCA1 acts as an acidic transcription factor. In fact, BRCA1 was 
later found to be a component of the RNA polymerase II holoenzyme. However, 
BRCA1 seems to be implicated in many aspects of transcription, although it is 
unlikely that it acts as a classical transcription activator but rather as a co-activator. It 
was also observed that the RING finger, an E3 ubuquitin ligase domain rather 
functions here as a protein-protein interaction motif and mediates the binding of 
BRCA1 to its partner BARD1. BARD1 also contains a BRCT and a RING finger 
domain, and both proteins dimerize via their RING finger domains. The biochemical 
function of this double RING domain was revealed to serve as an efficient E3 
ubiquitin ligase with strong preference for polyubiquitination. Although 
polyubiquitination was associated with targeting proteins for degradation, it also 
seems to participate in the DDR as a mediator or adaptor (Scully et al., 2004), 
(Billack et al., 2005). Several other proteins bind to the C-terminal BRCT domains of 
BRCA1. One of those BRCT interacting proteins is CTBP interacting protein (CtIP) 
that as the name implies bind CTBP, a transcriptional co-repressor. This gives further 
evidence that BRCA1 acts in transcriptional regulation eventually by targeting the 
CtBP pathway of transcriptional repression. In addition, a stable BRCA1-CtIP 
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complex is required for BRCA1-mediated tumor suppression (Yu et al., 1998). 
Another BRCA1 BRCT interacting protein is BACH1 (BRCA1 associated carboxyl-
terminal helicase 1), a member of the DEAH helicase family (also known as BRIP or 
FancJ). A solid interaction between BRCA1 and BACH1 is required for a proper 
execution of DSB repair. Mutations that lead to abrogation of the interaction increase 
the risk of cancer development (Cantor et al., 2001). Recent studies found that the 
BRCA1 BRCT domain also interacts with RAP80, a ubiquitin-binding protein 
(Sobhian et al., 2007). Fluorescent microscope analysis revealed BRCA1 also to co-
localize and form a complex during homologues recombination and meiotic prophase 
with RAD51 recombinase, an important component of the HR pathway that binds 
single-stranded DNA (Scully et al., 2004). In summary, through its C-terminal BRCT 
domains, BRCA1 may serve as an adaptor in phosphorylation-dependent protein-
protein interaction networks that are regulated by various kinases either in a cell 
cycle-dependent manner or in response to DNA damage. 
The wide operating range of BRCA1 highlighted by the broad band of interaction 
partners demonstrates its fundamental role in the DNA damage response and its 
importance as a tumor suppressor.  
 
 
 
Figure 4; Schematic overview of BRCA1 domains  
BRCA1 consists of 1863 amino acids and harbors an N-terminal RING finger domain a central located 
NLS and a C-terminal BRCT domain.  BRCA1 forms a heterodimer with BARD1 through its RING 
finger domain and the BRCT domain was also shown to interact with BACH1, CtIP and RAP80 in a 
phosphorylation dependent manner.  
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2.5. The FHA domain 
 
Each cell represents a dynamic complex that grows, divides differentiates and reacts 
to environmental influence. Communication within the cell is absolutely necessary 
therefore a highly conserved signal transduction system connects and regulates all 
kinds of pathways ensuring cell survival. Signaling protein modules are small 
independently folded units having a variety of functions. An important class of 
signaling modules are the protein-binding domains recognizing phosphorylated 
epitopes. This class of signaling modules comprises the SH2, PTB and WW domains, 
14-3-3 proteins and the subject of this chapter, the forkhead associated (FHA) 
domain. The evolution of phosphopeptide-recognizing and -binding modules is not 
surprising as kinase-dependent singal transduction pathways play a major role in 
almost all aspects of eukaryotic cellular function. 
The FHA domain was discovered in 1995 (Hofmann and Bucher et al., 1995) and is a 
modular phosphopeptide binding domain with a striking specificity for 
phosphothreonine (pT) –containing epitopes. So far, the FHA domain has been found 
in more than 700 different proteins in species ranging from prokaryotes to higher 
eukaryotes. The FHA domain is not only associated with intracellular signal 
transduction, but also with proteins involved in numerous processes including 
transcription, protein transport, DNA repair and protein degradation (Durocher and 
Jackson et al., 2002). The FHA domain received its name after it was found in 
forkhead transcription factors. Surprisingly, only five amino acids are identical in 
most FHA domains consisting of 80 to 120 amino acids (Hofmann and Bucher  et al., 
1995). Four of these conserved amino acids are required for phospho-epitope 
interactions. Even though FHA domains show little sequence homology they are all 
structurally organized into a -sandwich of six-stranded and five-stranded -sheets. 
Three contiguous loops connecting -strands from the five-stranded -sheet form the 
contact interface to phosphorylated interaction partners (see Figure 5). The five 
conserved loop residues are surrounded by residues that differ among FHA domains 
in order to yield binding specificity (Liang et al., 2008). However, the FHA binding 
specificity is additionally influenced by the amino acid residues surrounding the 
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phospho-acceptor. The residue, mostly at pT +3 position but other positions are also 
possible (Durocher et al., 2000).  
 
 
 
Figure 5; Crystal structure of the Rad 53 FHA domain 
(Adapted from Durocher and Jackson, FEBS, 2002) 
FHA domains are conserved phosphorylation dependent interaction modules comprising 80 to 120 
amino acids. FHA domains are associated with intracellular signal transduction, transcription, protein 
transport, DNA repair and protein degradation. FHA domains are structurally organized as a six-
stranded and five-stranded -sheet, forming a -sandwich.  
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2.6. The BRCT domain 
 
The BRCT (BRCA1 C-terminal) domain, first identified in BRCA1, is an 
evolutionarily conserved module that exists in a large number of proteins from 
prokaryotes to eukaryotes. BRCT domains are predominantly found in proteins 
involved in DNA damage checkpoint, recombination events and DNA repair (Koonin 
et al., 1996), (Bork et al., 1997), (Callebaut and Mornon et al., 1997). Sequence 
analysis revealed the presence of 50 copies of the BRCT domain in 23 different 
proteins, including 53BP1, RAD9, XRCC1, RAD4, Ect2, REV1, Crb2, RAP1, 
terminal deoxynucleotidyltransferase (TdT) and three eukaryotic DNA ligases. BRCT 
domains are not always located at the C-termini of the proteins and despite they often 
appear in a tandem configuration (i.e. two consecutive BRCT domains in close 
proximity) they can also be found in a single copy or in multiple copies. BRCT 
domains usually comprise 80 to 100 amino acids and form an autonomous folded 
globular complex. X-ray crystallographic and nuclear magnetic resonance studies 
revealed a structure of three -helices surrounding a central -sheet composed of four 
parallel -strands (see Figure 6). The structure is additionally stabilized by a salt-
bridge and various hydrophobic interactions between -helices and -strands (Zhang 
et al., 1998).  
It was recently demonstrated that tandem BRCT domains like FHA domains are 
phosphopeptide-binding motifs. In contrast to the FHA domain, it appears that 
tandem BRCT domains have a preference for phosphoserine and phosphothtronine 
residues. Thus, as SQ or TQ sequences are ATM phosphorylation consensus motifs, 
ATM is in many cases supposed to play a considerable role in the interplay with 
BRCT containing proteins (Manke et al., 2003), (Yu et al., 2003). The members of 
the BRCT domain-containing protein-family are usually large, multidomain proteins 
and besides BRCT domains, all of them, feature other functional domains involved in 
transcription, repair and replication or in other signal transduction events. Some of 
these proteins show enzymatic activity such as poly (ADP-ribose) polymerase 
(PARP), two DNA ligases and type X DNA polymerase whereas other members 
possess a RING-finger domain such as BRCA1, a FHA domain such as MDC1 or a 
DH domain such as ECT2 (Bork et a., 1997) 
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Figure 6; X-ray structure of the XRCC1 BRCT domain 
(Adapted from Zhang and Morera, EMBO journal, 1998) 
BRCT domains are evolutionarily conserved modules that occur alone, in tandems or in multiples and 
are predominantly found in proteins involved in cell cycle checkpoint, recombination or repair. They 
comprise 80 to 100 amino acids in which two to three  helices surround a central -sheet comprising 
four parallel -strands. BRCT domains are also phosphopeptid-binding motifs.  
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3. Materials and Methods 
 
 
3.1. Materials 
 
3.1.1. Antibodies 
 
3.1.1.1. Primary Antibodies 
 
Polyclonal mouse -GFP (1:1000)    Abcam 
Monoclonal mouse -Flag M2 (1:1000)   Sigma 
Monoclonal mouse -Tubulin (1:2000)   Sigma 
Polyclonal rabbit -Flag (1:300)    Sigma 
Rabbit -Bach1 (1:4000) a Gift from Josef Jiricny  
Rabbit -CtIP (1:4000) a Gift from Alessandro Satori 
TOM -ATM antibody (1:400) a Gift from Graeme Smith (KuDos 
Pharmaceutical) 
 
3.1.1.2. Secondary Antibodies 
 
Polyclonal ECL -mouse horseradish peroxidase-linked sheep antibody (1:5000) GE Healthcare 
Polyclonal ECL -rabbit horseradish peroxidase-linked donkey antibody (1:5000) GE Healthcare 
 
 
3.1.2. Antibiotics 
 
Ampicilin (100mg/ml in dH2O)    Fluka Chemie AG 
G418 sulfate, cell culture tested    Calbiochem 
Kanamycin      Fluka Chemie AG 
Penicillin-Streptomycin (10’000 units/ml)   Invitrogen 
 
 
3.1.3. Bacteria strains 
 
E.coli XL1blue       
E.coli pLys S       
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3.1.4. Chemical reagents 
 
Acetic Acid      Thommen Furler AG 
Acrylamid-bis 40%     Serva 
Adenosintriphosphat      A kind gift from Manuel Stucki 
Agarose       Promega Corporation 
Ammoniumperoxydisulfat     Fluka 
Bestatin       Bachem 
-mercapto-ethanol     Fluka 
Bromphenol blue sodium     Sigma-Aldrich 
Calcium Chloride dihydrate    Fluka 
Citric Acid      Merck 
Coomassie Brilliant Blue R250    Fluka 
Copper Sulfate (CuSO4(5H2O))    Merck 
Disodiumhydrogenphosphat dihydrate   Fluka 
Dithiothritol       Fluka 
DMEM       Gibco 
DMSO       Fluka 
ECL (two solutions, mixed 1:1)    Amersham Biosciences 
Ethylendiamin-tetraacetic acid    Fluka 
Enlightening solution     Amersham Bioscience 
Ethanol       Merck 
Ethidium bromide solution 1% in H2O   Fluka 
Fetal calf serum (FCS)     Gibco 
Flag M2 agarose     Sigma 
Folin-Ciocalteu’s phenol reagent    Sigma 
Formaldehyde (HCHO)     Fluka 
32P-ATP      Hartmann Analytic 
Gluacal acetic acid     Fluka 
D(+) Glucose monohydrate    Fluka 
Glutathione       Sigma 
GSH-Sepharose      GE Healthcare 
Glycerol       Fluka 
Hydrochloride acid (HCl)     Merck 
HeLa nuclear extract      selfmade 
4-(Hydrosyethyl) piperazine-1-ethanesulonic acid   Fluka 
Isopropanol      Sigma 
Isopropyl--D-thiogalactopyranoside    Biosynth  
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KOH 
Leupeptin      Bachem 
Methanol      Merck 
Magnesium chloride (MgCl2)    Fluka 
MgSO4       Fluka 
NaHPO4      Fluka 
Nonidet P40       Fluka 
Pepstatin      Bachem 
Phenylmethansulfonylfluorid     Fluka 
Ponceau S      Sigma 
Protein A-Sepharose     GE Healthcare 
S-protein Agarose     Novagen 
Sodiumdodecylsulfat     Fluka 
Silver nitrate (AgNO3)     Fluka 
Sodium carbonate (Na2CO3)    Fluka 
Sodium chloride (NaCl)     Fluka 
Sodium citrate (Na3H5C6O2)    Fluka 
Sodium hydroxyde (NaOH)    Fluka 
Streptavidin agarose     Fluka 
Streptavidin dynabeads     Invitrogen 
N,N,N’,N’-Tetramethylethylendiamin   Fluka 
Tris-(hydrosymethyl)-aminomethan   Biosolve 
Trypsin-EDTA (10x)     Invitrogen 
Tween 20      Fluka 
Xylen Cyanol      Merck 
 
1.5 Enzymes 
 
BamHI       New England Biolabs 
CIP (calf intestine phosphatase)    New England Biolabs 
DpnI       Stratagene 
Expand High Fidelity  Enzyme (100U/μl) Mix  Roche 
Pfu Turbo Polymerase     Stratagene 
Pfu Ultra Polymerase     Stratagene 
Pfu UltraII Polymerase     Stratagene 
T4-DNA-Ligase      Fermentas 
T4 PNK       New England Biolabs 
XbaI       New England Biolbas 
XhoI       New England Biolabs 
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3.1.6. Human cell lines 
 
293T        
U2OS        
 
3.1.7. Vectors 
 
pEYFPnucTO human expression vector    BD Biosciences Clontech 
pGEX4T3 bacterial expression vector    GE Healthcare Bioscience 
 
 
3.2. Methods 
 
3.2.1. DNA manipulations 
 
3.2.1.1. Agarose Gelelectrophoresis 
 
Digested plasmid DNA or PCR products were separated on a 1% agarose gel and visualized by 
ethidium bromide staining under a UV light source.  
 
Buffers and Medias: 
1x TAE buffer 
6x Loading buffer 
1kb Marker 
 
Chemical Reagents: 
Agarose      
Ethidium bromide solution 
 
Electrophoresis Kit: 
Mini Sub DNA Cell     Bio-Rad electrophoresis system 
Power Pac 200 (at 80V)     Bio-Rad power supplies 
ChemiImager 5500 Alpha Innotech 
 
Gel preparations: 
100ml 1xTAE buffer 
1g Agarose 
4μl Ethidium bromide solution 
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3.2.1.2. SDS-PAGE (SDS-polyacrylamid gel electrophoresis) 
 
SDS-PAGE is a method to separate proteins according their molecular weight in a matrix by applying 
an electric field through the gel. 
 
Buffers: 
2x SDS loading buffer 
1x Stacking-Gel buffer 
2x Running-Gel buffer 
1x Running buffer 
Stain 
Destain 
 
Electrophoresis Kit: 
Mini-Protean Tetra Electrophoresis System   Bio-Rad vertical electrophoresis system 
Power Pac 200 (15min 80V, than 150V)   Bio-Rad power supplies 
 
Gel preparation: 
 6% 8% 10% 12% 15% Stacking gel 
2x Gel buffer 2.5ml 3ml 3ml 5ml 5ml 5ml 2.4ml 
40% Acrylamid-bis (w/v) 0.75ml 1.2ml 1.5ml 2.5ml 3ml 3.75ml 0.375ml 
dH2O 1.75ml 1.8ml 1.5ml 2.5ml 2ml   
APS 10% 50l 60l 60l 100l 100l 100l 30l 
TEMED 10l 10l 10l 15l 15l 15l 8l 
 
 
3.2.1.3. DNA-Digestion 
 
DNA was digested for at least 2 hours at 37°C 
 
Preparations: 
5μl H2O 
3μl DNA (1μg/μl) 
1μl Buffer       
0.5μl Restriction enzyme 1     
0.5μl Restriction enzyme 2     
 
After digestion, CIP phosphatase was added to the mix for 1 hour at 37°C to avoid self-ligation of the 
empty vector by phosphorylating 5’-ends.  
 
1μl CIP      New England Biolabs 
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3.2.1.4. NucleoSpin  Gel-Extraction and PCR clean-up 
 
The gel extraction and PCR clean-up was done according the Macherey-Nagel protocol (protocol at a 
glance, rev. 03) for NucleoSpin Extract II by using mini spin columns with silica membrane 
technology. 
 
Buffers and Medias: 
NT binding buffer     Macherey-Nagel 
NT3 wash buffer      Macherey-Nagel 
NE elution buffer      Macherey-Nagel 
 
Material: 
NucleoSpin mini spin columns 
 
3.2.1.5. Ligation Arrangements 
 
Digested DNA fragments were ligated by T4 DNA ligase in the fridge at 4°C over night. 
 
Preparations: 
1μl   T4 DNA Ligase     Fermentas   
1μl T4 Ligase Buffer     Fermentas 
4μl Template        
4μl Insert        
 
3.2.1.6. Mini Plasmid Preparation (Mini Prep) 
 
To quantify and analyse recombinant plasmid DNA the following protocol was used: 
The cell pellet from an overnight bacteria culture was collected by centrifugation (4000rpm for 10 
minutes at 4°C) and resuspended in 250μl S1 buffer. When the pellet was well dissolved the S2 buffer 
was added for cell lysis and three minutes later the S3 buffer was added to precipitate proteins. The 
mix was centrifuged at 14000rpm for 15 minutes at 4°C. The supernatant was collected, mixed with 
560μl isopropanol and incubated on ice for 10 minutes.  After that, the mixture was centrifuged at 
14000rpm for 30 minutes at 4°C, the supernatant was then discarded, 500μl ethanol were added to the 
pellet and the mixture was again centrifuged at 14000rpm for 10 minutes. The supernatant was 
discarded immediately and the pellet was air-dried. The dried pellet was dissolved in 40μl dH2O.  
 
Buffers: 
S1 Resuspenson buffer     Macherey-Nagel 
S2 Lysis buffer      Macherey-Nagel 
S3 Eluation buffer     Macherey-Nagel 
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3.2.1.7. NucleoBond Plasmid Purification (Midi Prep) 
 
Protocol: 
Bacteria was cultured overnight in 120ml LB medium and harvested by centrifugation at 6000rpm for 
15 minutes at 4°C. The cell pellet was carefully resuspended in 4ml S1 buffer (RNAse added) and 
placed in a 50ml Falcon tube. Subsequently, 4ml S2 buffer were added to the mixture and incubated at 
room temperature for 3 minutes. Then, 4ml pre-cooled S3 buffer were added and the mixture was 
incubated on ice for 5 minutes. At the same time, an AX 500 (Maxi) column was equilibrated with 
2.5ml N2 buffer. Afterwards a pre-wetted Nucleobond folded filter was placed in a funnel and placed 
on the column. The bacterial lysate was loaded onto the filter and the column was washed with 10ml 
N3 buffer.  The bound plasmid DNA was eluted in 5ml N5 buffer and collected in a 10ml Falcon tube. 
To precipitate the eluted DNA 3.5ml isopropanol were added, mixed carefully and centrifuged for 30 
minutes at 4600rpm at 4°C. The supernatant was discarded, while 2ml ethanol were added to the cell 
pellet. The mix was briefly vortexed and centrifuged at 4600rpm for 10 minutes at room temperature. 
All ethanol was carefuly removed by pipetting and the pellet was allowed to dry. Finally, the dry pellet 
was dissolved in 40μl dH2O. 
 
Material: 
Sorvall RC 5C Plus     Sorvall centrifuges 
Sorvall SLA3000      Sorvall centrifuge rotors 
250ml Sorvall tubes     Sorvall tubes 
AX 500 (Maxi) column     Nucleobond columns 
Nucleobond folded filter     NucleoBond filters 
Rotanta 460      Hettrich Zentrifugen AG 
 
Buffers and Medias: 
S1 Resuspenson buffer     Macherey-Nagel 
S2 Lysis buffer      Macherey-Nagel 
S3 Eluation buffer     Macherey-Nagel 
N2 Wash buffer      Macherey-Nagel 
N3 Elution buffer      Macherey-Nagel 
N5 Elution buffer      Macherey-Nagel 
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3.2.1.8. Polymerase Chain Reactions (PCRs) 
 
3.2.1.8.1. Expand High Fidelity PCR System 
 
The Expand High Fidelity PCR Kit (Roche) includes the following contents: 
 
- Expand High Fidelity Enzyme Mix  
- Expand High Fidelity buffer (10x) with 15 mM MgCl2 
- Expand High Fidelity buffer (10x) without MgCl2 
- MgCl2 25 mM Stock Solution 
 
 Enzyme storage buffer: 20mM Tris-HCl, pH7.5 (25°C), 100mM KCl, 1mM Dithiothritol (DTT), 0.1 
mM EDTA, 0.5% Nonidet P40 (v/v), 0.5% Tween 20 (v/v), 50% glycerol 
 
Additional Material: 
 
- dNTP-Mix (deoxynucleotide mix) 
- 0.2 ml thin-walled PCR tubes (Axygen PCR 02-C) 
- Thermal block cycler (Applied Biosystems GeneAmp PCR System 2700) 
 
The PCR reaction mix was prepared according the Expand High Fidelity PCR System protocol: 
 
Volume  Reagent     Final Concentration 
4.125μl dH2O       
2.5μl 10x Expand High Fidelity buffer (without MgCl2)   
5μl MgCl2 (25mM) 
2μl dNTP-Mix     200μM 
1μl dsDNA template    1-10ng 
5μl Forward primer    300nM 
5μl Reverse primer     300nM 
0.375μl Expand High Fidelity enzyme mix  1.7U/reaction 
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Thermal cycling: 
 
   Cycles   Temperatur   Time 
 
Initial Denaturation 1x   94°C    5 min  
 
Denaturation     94°C    2 min 
    
Annealing  30x   55°C    30 s 
   
Elongation     72°C    2 min 
 
Final Elongation  1x   72°C    7 min  
 
Cooling      4°C     
 
 
3.2.1.8.2. Site-directed Mutagenesis 
 
“In vitro” Stratagene QuickChange Site-Directed Mutagenesis is a method to generate point 
mutations that can lead to amino acid changes and/or deletions or insertions of single or multiple 
amino acids. The standard method developed by Stratagene utilizes a supercoiled double-stranded 
DNA vector and two synthetic oligonucleotide primers featuring the desired mutation (see Figure 7). 
Mutation primers were designed according to recommendations of the Stratagene QuickChange Site-
Directed Mutagenesis manual and synthesized by Microsynth AG. Site-directed mutagenesis was also 
accomplished according to recommendations using the Stratagene QuickChange Site-Directed 
Mutagenesis Kit with a PfuTurbo, Pfu Ultra or Pfu Ultra II DNA polymerase (2.5 U/μl).  
 
 
 
Figure 7; Overview of the site-directed mutagenesis method 
(Adapted from Stratagene QuickChange Site-Directed Mutagenesis Kit manual) 
Step 1: The procedure utilizes a gene on a plasmid with the target site for mutation. Step 2: Two 
synthetic oligonucleotide primer containing the desired mutation anneal to the denaturated plasmid and 
are extended during temperature cycling by a PfuTurbo, Pfu Ultra or Pfu Ultra II DNA polymerase. 
Step 3: Incubation with Dpn1 is required to digest the parental methylated and hemimethylated DNA 
template. Step 4: Finally, nicked DNA containing the desired mutation is transformed into highly 
competent E.coli XL-blue cells.  
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The PCR reaction mix was prepared according the Stratagene QuickChange Site-Directed 
Mutagenesis protocol:      
 
5μl  10x Reaction buffer 
1μl dNTP-Mix       
5-50ng dsDNA template     
125ng  Forward primer  
125ng Reverse primer  
1μl Pfu polymerase 
 dH2O was added to a final concentration of 50μl 
 
Thermal cycling: 
 
   Cycles   Temperatur   Time  
 
Initial Denaturation 1x   95°C    30 s 
 
Denaturation     95°C    30 s 
    
Annealing  18x   55°C    1 min 
   
Elongation     68°C  1.5min/kb of plasmid length 
 
Cooling      4°C     
 
 
To digest the parental DNA the mix was incubated with 1μl DPN1 for 1 hour at 37°C.  
 
The Stratagene QuickChange Site-Directed Mutagenesis Kit includes the following contents: 
 
- DNA polymerase (2.5U/μl) 
- 10x Reaction buffer 
 
Additional material: 
 
- dNTP-Mix (deoxynucleotide mix) 
- 0.2 ml thin-walled PCR tubes     Axygen PCR 02-C 
- Thermal block cycler  Applied Biosystems GeneAmp PCR 
System 2700 
 
 
 
 
Materials and Methods 
28 
3.2.1.9. Preparation of chemically competent E.coli cells 
 
To acheive a better transformation efficiency, E.coli cells were converted into chemically competent 
cells according the following protocol: 
 
3ml LB medium was inoculated with XL1blue E.coli strain and incubated over night at 37°C. The 
overnight culture was added to 500ml SOB++ medium and incubated at 25°C until the absorbance at 
600nm was 0.5. The culture was kept on ice for 10 minutes. The cell suspension was centrifuged at 
4500rpm for 10 minutes at 4°C. The resulting pellet was resuspended in 100ml ice-cold TB buffer. The 
suspension was again kept on ice for 10 minutes. After centrifugation at 4500rpm for 10 minutes at 
4°C, the pellet was gently resuspended in 18.6ml ice-cold TB buffer complemented with 1.4ml DMSO. 
The mix was incubated on ice for 10 minutes. The suspension was aliquoted in pre-cooled Eppendorf 
tubes (600μl per tube), shock-frozen in liquid nitrogen and stored at -80°C. 
 
Material: 
Cuvettes  (halb-mikro)     Greiner Bio One  
Genesis 10UV scanning     Digitana AG thermo spectronic systems 
Sorvall RC 3C Plus     Sorvall centrifuges 
Sorvall HRL6      Sorvall rotors 
Nalgene 1000ml tubes 
 
Buffers and Medias: 
LB medium 
SOB++ medium 
TB buffer 
 
Chemical Reagents: 
DMSO 
 
3.2.1.10. Heat-shock transformation of chemically competent E.coli cells with plasmid DNA 
 
Transformation is a method to get foreign DNA into a recipient bacteria cell. 
 
Protocol: 
50μl of chemically competent cells were thawed on ice and mixed with 1 to 10μl of a solution 
containing the plasmid DNA. The mix was kept on ice for 30 minutes before heat shocked at 42°C for 
45 seconds on the heating block. After the cells were again incubated on ice for 90 seconds, 400μl of 
SOC medium were added. The cells were then cultured in the shaking incubator at 37°C for 40 
minutes. The cell suspension was then spread on agar plates by small sterile glass beads.  
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Buffers and Medias: 
SOC 
 
Bacteria cells: 
E.coli XL1blue      were present in the Stucki lab 
E.coli BL21 pLys S     were present in the Stucki lab 
 
3.2.1.11. Sequencing 
 
Mini Plasmid Preparations (Mini Preps) were sequenced by Microsynth GMBH, using standard 
sequencing primers provided by Microsynth. The plasmid DNA was diluted in dH2O to an end 
concentration of 0.8μg/10μl. 
 
 
3.2.2. Protein manipulations 
 
3.2.2.1. Determination of protein concentrations by Bradford or Lowry 
 
To determine protein concentrations of cell extracts, two different methods were used dependening 
upon how the cell extracts were prepared. While protein concentrations of SDS extracts were measured 
by the Lowry assay, the Bradford analysis method was used for NP40 extracts, respectively. In both 
assays the absorbance (Bradford: 595nm, Lowry: 750nm) of four Bovine Serum Albumin (BSA) 
standard solutions was first measured to calculate a standard curve of absorbance. This resulting curve 
was used to determine the protein concentration of the samples. 
 
Material: 
Cuvettes  (halb-mikro)     Greiner Bio One  
Genesis 10UV scanning     Digitana AG thermo spectronic systems 
Albumin from bovine Serum, Biochemika Fraction V  Fluka Chemie AG 
 
3.2.2.2. NP40 Extract 
 
The NP40 extraction method is not as harsh as the SDS extraction because proteins are not denatured 
in the process and interactions between proteins can still be analyzed. In contrast, the total amount of 
proteins obtained is smaller, because only soluble proteins can be extracted by this method.  
 
Protocol: 
Cells were washed in PBS and trypsinized. After inhibiting trypsin with DMEM, the cell suspension 
was centrifuged for 1 minute at 1500rpm. Subsequently, the pellet was washed twice with PBS before 
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the cells were resuspended in 100μl Buffer E (10cm plate). The suspension was frozen at -80°C and 
thawed on ice again. After the cells were spun down at 14000rpm for 10 minutes the supernatant was 
used for further experiments.  
 
Buffers and Medias: 
Buffer E 
DMEM (incl. 10% FCS, 1% Pen Strep) 
PBS 
Trypsin-EDTA 
 
3.2.2.3. SDS Extract 
 
Protocol: 
Cells were first washed with PBS before 250μl of Extraction buffer were added, so that the cells could 
be scratched off with the rubber spatula. In order to lower viscosity of the cell extract, it was passed 
several times with force through a small syringe needle which resulted in sharing of the chromatin. 
This was repeated until the viscosity was low enough to allow pipeting. An aliquot of 10μl was 
removed and protein concentration was analyzed by Lowry assay.  
 
Buffers and Medias: 
Blue dye 
Extraction buffer 
PBS 
Solution A 
Solution B 
 
3.2.2.4. Western Blot 
 
Western Blot is a technique, where proteins separated by SDS-PAGE are transferred onto a membrane 
and subsequently detected by immunological methods.  
 
Protocol: 
The SDS-gel was transferred on a nitrocellulose membrane for 1 hour with 250mA using the Mini 
Trans-Blot Cell from Bio Rad. To evaluate marker bands and success of blotting procedure the 
membrane was stained with Ponceau S. The blot was then incubated with 5% TBST-milk for 2 hours 
to block unspecific binding sites for the antibodies. Subsequently, the membrane was washed three 
times with TBST, before the primary antibody, diluted in 2.5% TBST-milk was added. The incubation 
was done on a parafilm coated glass plate in a wet chamber for time periods between 4 hours and 
overnight. The membrane was washed three times in TBST and was incubated for one hour with the 
secondary antibody which was also diluted in 2.5% TBST-milk (1:5000). After the incubation, the blot 
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was washed three times in TBST again. 1ml of ECL Western Blot detection solution (1:1 mix) was 
added to the blot for 1 minute. Then, the membrane was immediately wrapped into saran foil and 
exposed to X-ray films. 
 
When the membrane was incubated with another primary antibody the blot had to be stripped first for 
one hour in stripping buffer. Before incubation with the primary antibody the blot was washed three 
times in TBST. 
 
Material: 
Mini Trans-Blot cell     Bio-Rad blotting systems 
Power Pac 200       Bio-Rad power supplies 
Nitrocellulose membrane     GE Water & Process Technologies 
Typon optimax      Raymed Imaging AG 
Contatyp medical X-ray film    Typon Holding AG 
 
Buffers and Medias: 
ECL (two solutions, mixed 1:1)    Amersham Biosciences 
TBST 
5% TBST-milk 
Transfer buffer 
Stripping buffer 
 
3.2.2.5. Silver Staining of protein gels 
 
Protocol: 
First the gel was incubated in 100ml of 50% methanol for 15 minutes, then in 100ml of 5% methanol 
for 15 minutes and in 100ml dH2O containing 3.2μl of 1M DTT for 15 minutes. The gel was briefly 
washed in dH2O twice. Afterwards a little silver solution was added and poured away before the gel 
was incubated with the rest of the silver solution for 15 minutes. Again the gel was shortly washed 
twice with dH2O, followed by two short washing steps with developing solution. The gel was then 
incubated with the rest of the developing solution until the bands reached the desired intensity. To stop 
the chemical reaction solid citric acid was slowly sprinkled into the solution until the fizzing ceased. 
Finally, the gel was washed three times in dH2O for 15 minutes. 
All incubations were carried out in fresh made solutions in a clean plastic box at room temperature 
with gentle shaking on a shaking platform.  
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Buffers and Medias: 
50% methanol  
5% methanol 
Silver solution 
Developing solution 
 
Chemical reagents: 
DTT 
Nitric acid 
 
3.2.2.6. Pull down arrangement 
 
All pull downs were arranged according the following protocol: 
The frozen cell pellet was thawed on ice before resuspended in 1.5ml NTEN buffer. The suspension 
was incubated on ice for 10 minutes again. The cell extract was cleared by centrifugation with 
14000rpm, at 4°C for 10 minutes. The supernatant was decanted into a 2ml Eppendorf tube, while the 
pellet was discarded. The supernatant was incubated with different amount of equilibrated beads 
(between 20 and 40μl of Flag M2 agarose, S-protein agarose, Streptavidin agarose*) for at least one 
hour at 4°C with agitation. Equilibration means to wash beads three times for fife minutes with NTEN 
buffer. After the incubation the tube was centrifuged at 1500rpm so that beads assembled at the 
bottom. The supernatant was discarded and beads were washed three times in 1.5ml NTEN buffer. For 
each washing step, beads were placed on the shaker for 5 minutes. 25μl SDS loading buffer were 
added to the washed beads and heated up to 100°C for 3 minutes on the heating block. Samples were 
loaded on an SDS gel in order to analyze them by Western Blotting or by silver staining.  
  
*To assemble beads in pull downs using Streptavidin dynabeads, the tube was placed on the magnetic 
hanger instead of centrifugation.  
 
Buffers: 
NTEN buffer  
SDS loading buffer 
 
Chemicals: 
Flag M2 agarose 
S-protein agarose 
Streptavidin agarose 
Streptavidin dynabeads 
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3.2.2.7. Production of GST-fusion proteins 
 
Protocol: 
Transformed BL21 pLys S bacteria cells were cultured in 500ml LB-medium containing ampicillin 
(50μg/ml) until they reached an OD600 of 0.6. 50μl IPTG of a 0.5M stock solution were added which 
initiated the expression. Three hours after the expression start the cells were collected by centrifugation 
and the pellet was frozen (-80°C) twice and rethawed. The pellet was then resuspended in 10ml E1A 
lysis buffer and was sonicated until the color of the extract changed to opaque. After centrifugation, the 
supernatant was incubated with 1ml of 50% equilibrated GSH-Sepharose for 15 minutes at 4°C. The 
mixture was poured into a glass wool filter column (self-made) followed by six washing steps with 5ml 
ELB buffer. The fusion protein was eluted by the addition of six times 0.5ml of a 20mM GSH solution, 
resulting in six different fractions. The protein quality was estimated by a coomassie stained SDS-
PAGE. The fractions with the highest protein concentration were pooled and dialysed against Dialysis 
buffer using the Spectra/Por Dialysis Membrane for 4 hours. Finally, the concentration was measured 
by Bradford analysis and diluted to 1mg/ml. 
 
Material: 
Cuvettes  (halb-mikro)     Greiner Bio One  
Genesis 10UV scanning     Digitana AG thermo spectronic system 
Cell disrupter B15     Branson sonifier 
250ml Sorvall tubes      Sorvall tubes  
Sorvall RC 5C Plus     Sorvall centrifuges 
Sorvall SLA 1500     Sorvall rotors   
Spectra/Por Dialysis Membrane 3500 MWCO  Spectrumlab 
 
Buffers: 
Dialysis buffer 
E1A lysis buffer 
ELB buffer 
1x TBS buffer 
 
Chemical Reagents 
Ampicillin 
10% glycerol 
GSH (20mM) 
GSH-Sepharose 
IPTG 
LB-medium 
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3.2.2.8. ATM Kinase Assay 
 
Protocol: 
To immuno precipitate ATM, 100μl HeLa nuclear extract (HNE), 100μl Buffer D and 200μl IP buffer 
were mixed, complemented with 1μl TOM -ATM antibody and incubated for 2 hours at 4°C. 25μl 
Protein A-Sepharose (50% equilibrated with IP buffer) were added and incubated for 2 hours at 4°C. 
The solution was washed four times with 1ml IP buffer followed by two washes with 1ml kinase 
buffer. After the last wash the supernatant was completely decanted and the beads were resuspended in 
17μl kinase buffer and 1μl of the GST-fusion protein (wild type and T4A mutant MDC1 FHA domain) 
was added. The reaction was initiated by the addition of 2μl of ATP (0.5mM) spiked with 0.5μl 32P-
ATP (3000 Ci/mmol) and maintained for 30 minutes at 30°C. Subsequently, the mix was centrifuged at 
14000rpm for 1 minute. To stop the reaction 10μl of SDS loading buffer were added to 20μl of the 
supernatant and heated at 100°C for 3 minutes. All samples were loaded on a 12% acrylamid gel. The 
gel was fixed (40%MetOH, 10% acetic acid) and soaked in Enlightening Solution. The gel was then 
exposed to X-ray film overnight.  
 
Buffers and Medias: 
Buffer D 
IP buffer 
Kinase buffer 
SDS loading buffer 
 
Chemical Reagents: 
Acetic acid 
TOM -ATM antibody 
ATP 
Enlightening solution 
32P-ATP 
HeLa nuclear extract 
MetOH 
Protein A-Sepharose 
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3.2.3. Manipulations with human cell lines 
 
3.2.3.1. Calcium phosphate transfection 
 
In general, transfection is a method to bring foreign DNA into cells of higher eukaryotes. 
 
To transiently express desired proteins in human cells, 293T transformed human embryonic kidney 
cells were transfected by calcium phosphate. Because the transfection efficiency is best when the cell 
are about 50% confluent, cells were split on the previous day so that they reached 50% confluency on 
the day of transfection. A glass coverslip was placed in each dish to control the efficiency of the 
transfection by fluorescent microscopy.  
 
Preparations: 
The required amount of DNA (1μl/μg) was first diluted in dH2O. This mix was slowly added to 2x 
HBS prepared in a 10 ml Falcon tube. Subsequently, the CaCl2 solution was carefully added to the mix 
under gentle agitation of the falcon tube.  
 
Mixing proportions depend on dish size: 
 
Plate size 2x HBS DNA (1μl/μg) dH2O CaCl2(2M) 
6-well plate 100μl 2-5μg 87.5μl 12.5μl 
Small dish 240μl 5-10μg 210μl 30μl 
10cm dish 660μl 10-35μg 577.5μl 82.5μl 
15cm dish 1400μl 20-30μg 1225μl 175μl 
 
The mix was dropwise added to the cells and the culture was incubated at 37°C. After 24 hours of 
incubation the cells were washed once with PBS and then fresh medium was added. The cells were 
collected 48 hours past transfection and used for experiments.  
 
Buffers and Medias: 
2x HBS (pH adjusted to 7.09 with NaOH) 
2 molar CaCl2 solution 
 
3.2.3.2. Lipofectamin transfection  
 
Lipofectamin transfection was carried out to get stably transfected cell lines. Best transfection 
efficiencies were achieved around 50% confluency in 6cm dishes. U2OS cells were used to retrieve 
stably transfected cell lines. 
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Preparations: 
300μl Optimem and 15μl Lipofectamin were mixed and incubated for 10 minutes at room temperature. 
At the same time 300μl Optimem were mixed with 4μl DNA (1μl/μg). The two Optimem solutions 
were brought together and incubated for 20 minutes at room temperature. Subsequently, the cells were 
washed once with PBS and 3ml of pre-warmed DMEM containing 5% FCS were added. The DNA-
Lipofectamin was added dropwise to the 6cm dish.  
The next day the medium with 5% FCS was replaced with normal DMEM containing 10% FCS and 
antibiotics.  
 
Buffers and Medias: 
DMEM 
FCS 
Lipofectamin 
Optimem 
PBS 
 
3.2.3.3. DAPI staining 
 
DAPI (4,6-Diamidino-2-phenylindol) is a fluorescent dye that stains DNA. Hence, it is used as a 
marker of the nucleus in fluorescence microscopy. 
 
Protocol: 
Cells grown on coverslips, were washed twice with PBS before they were fixed in 50% methanol for 
10 minutes at 4°C. Subsequently, cells were washed twice with PBS, before the coverslips were placed 
cells-down on a drop of DAPI solution on parafilm. Coverslips were incubated in the dark for 10 
minutes and washed twice with PBS. Then, the coverslips were mounted on a microscopy slide with a 
drop of vectashield. The coverslips were immobilized on the slide by transparent nail polish.  
 
Material: 
Coverslips 
Glass slides 
Fluorescence microscope 
 
Buffers and Medias: 
PBS 
50% methanol 
Nail polish 
DAPI 
Vectashield 
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3.2.3.4. Selection of stably expressing cell clones 
 
In order to isolate stably transfected cell clones, the transfected cells were selected by means of an 
antibiotic resistance gene located on the expression construct. 
 
Protocol: 
After Lipofectamin transfection cells grew for two days on a 6 cm plate. The dish was washed once 
with PBS before 500ml trypsin-EDTA was added. After a short incubation period 3.5ml of medium 
were pipetted into the dish and the rest of the unsolved cells were released from the surface. Four 10cm 
dishes were prepared by adding 10ml medium containing G418 (90μl/ml). The cell suspension was 
diluted in three different ratios (1:10, 1:20, 1:33). The three dilutions were partitioned between three 
10cm dishes.  Non-transfected cells diluted at 1:10 ratio were resuspended in the fourth dish as a 
negative control.  
When the cell colonies reached a certain dimension, the cells were picked under the microscope. The 
individual clones were transferred to a 24-well plate that contained a coverslip in each well. After the 
clones reached a high density, coverslips were removed and the transfection success was controlled by 
fluorescence microscopy.  
Clones with the highest expression levels were expanded and frozen at -80°C. Extracts were prepared 
as described above. 
 
Buffers and Medias: 
DMEM (incl.10% FCS, Pen-Strep) 
G418 
PBS 
Trypsin-EDTA 
 
Material: 
24-well plate 
6/10/15cm dishes 
Coverslips 
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4. Goals of the thesis 
 
4.1. Identification of an ATM phosphorylation site in MDC1 
 
Previous data in our lab showed that MDC1 is phosphorylated in the N-terminal 
region by ATM. Two potential phosphorylation sites exist at the N-terminus of 
human MDC1: Thr4 and Thr98. Since deletion of the first nine amino acids of an N-
terminal MDC1 fragment (1-124) resulted in a protein that could not be 
phosphorylated by ATM in vitro, we assumed that Thr4 is the only residue that is 
targeted by ATM. Thus, the goal of this project was to directly prove that threonine 4 
is the actual residue at the MDC1 N-terminus that is phosphorylated by the ATM 
kinase.  
 
 
4.2. Development of a tandem affinity purification system in order to identify 
novel FHA and BRCT interaction partners 
 
The aim of the second project was to develop an “in vivo” pull down strategy to 
identify novel components of the DNA damage response. Many proteins involved in 
the DNA damage response feature conserved domains, such as FHA or BRCT 
domains that interact with other proteins in a phosphorylation-dependent manner. To 
detect novel interaction partners of such domains, we aimed to develop a strategy to 
trap them by overexpressing these domains in mammalian cells as tagged fusion 
proteins, followed by tandem purification and identification of interaction partners by 
mass spectrometry. As a first step, the goal of this thesis was to design the system and 
to test it in a proof-of-principle set up.  
Since three phospho-specific interaction partners for BRCA1 BRCT domains have 
already been identified (CtIP, Bach1 and RAP80; see also introduction), we decided 
to over express affinity-tagged BRCA1 BRCT domains as a bait in human cells to test 
if we could retrieve any of these proteins by our “in vivo” pull down strategy.  
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5. Results 
 
5.1. Identification of an ATM phosphorylation site in MDC1 
 
5.1.1. Introduction 
 
Previous data from our lab showed that deletion of the first nine amino acid residues 
of MDC1 prevented phosphorylation of a recombinant N-terminal fragment of MDC1 
by ATM. In order to directly show that T4 is targeted by ATM in vitro, Thr4 was 
replaced by Ala by site-directed mutagenesis and the protein was produced in 
bacteria. Finally, the purified protein was subjected to an in vitro ATM kinase assay 
to test whether replacement of Thr4 would affect the phosphorylation. 
Originally, we planned to mutate the Thr4 residue to Ala in an N-terminal MDC1 
GST fusion construct (amino acids 1-124; Spycher et al., 2008) using the Stratagene 
QuickChange Site-Directed Mutagenesis Kit. However, even after several attempts, 
the mutagenesis was not successful. Thus, an alternative approach was established. 
To generate a GST fusion protein, a fragment of the MDC1 cDNA comprising the N-
terminal FHA domain (aa 1-154) and bearing a T4A point mutation (generated by 
Stephanie Jungmichel) was subcloned into the pGEX4T3 bacterial expression vector. 
The pGEX4T3 vector already contains a GST tag in frame with a multiple cloning 
site.   
Since the restriction sites in the original plasmid (PEYFPnucTO_MDC1-FHAT4A) 
were not compatible with the pGEX vector, the fragment featuring the first 124 amino 
acids was isolated by the Expand High Fidelity PCR System. The utilized primers; 
M-1 T4A_fw and M_FHA_rev were provided by Stefanie Jungmichel and Christoph 
Spycher. The pGEX4T3 bacterial expression vector (GE Healthcare Bioscience) was 
linearized by digestion with BamH1 and Xho1. The vector was then purified by 
NucleoSpin Gel-Extraction. To clone the T4A mutated MDC1 FHA domain into 
the empty vector, the purified PCR fragment bearing the mutation was also digested 
with BamHI and XhoI, followed by ligation with T4 DNA ligase. The ligation 
reaction was transformed into E.coli XL1blue cells. Plasmid DNA isolated by a mini 
prep was test-digested with BamH1 and Xho1 in order to verify the ligation success. 
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All 7 tested E.coli clones contained the vector and the insert (see Figure 8). Best 
results (clone Nr. 4 and 7) were sent for sequencing to the Microsynth GmbH. 
Sequencing results revealed that the sub-cloning was successful (see appendix 
sequence report of the T4A mutant N-terminal fragment of MDC1). 
 
 
 
Figure 8; The test digest with BamH1 and Xba1 revealed a successful subcloning. 
 5μl of the 1kb marker and 10μl of the test digestion mix were loaded on a 1% agarose gel. The 
calculated size of the fragment is 469pb. M 1kb marker, 1.-7. samples. 
 
E.coli BL21 pLys S cells were transformed with pGEX4T3 carrying the T4A mutant 
fragment (pGEX4T3-MDC1-FHA(T4A)). In parallel, the wild type fragment 
(pGEX4T3-MDC1-FHA(WT)) was also purified as a positive control. Cells were 
cultured in LB to an OD600 of 0.6 before the expression of the GST-fusion protein 
was induced by IPTG. GSH-sepharose was used for the purification of the fusion 
protein. Subsequently, protein quality and quantity was estimated by SDS-PAGE and 
coomassie blue staining. Elution fractions 2 to 6 were pooled and diluted to 1μg/μl 
after the concentration was determined by the Bradford assay. In conclusion, the 
mutant as well as the wild type fusion protein was strongly expressed and well 
purified (see Figures 9 and 10), so they could be directly used for the intended 
experiments.  
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Figure 9; The T4A mutant fragment was well expressed 
The pGEX 4T3 vector bearing the T4A mutant fragment was transformed into E.coli BL21 pLys cells 
and the expression was induced by IPTG. The protein was purified using GSH-sepharose. 5μl of the 
high molecular weight (HMW) marker, 5μl of each elution fraction (EF) 1-6, 5μl wash (W), 5μl flow 
through (FT) and 5μl cell extract (CE) were loaded on a 10% SDS gel. The calculated size of the 
fusion protein is around 40kDa.  
 
 
 
 
Figure 10; The wild type fragment was very well expressed 
The wild type protein was also transformed into E.coli BL21 pLys cells and the expression was 
induced by IPTG. The wild type protein was purified using GSH-sepharose. 5μl of the high molecular 
weight (HMW) marker, 5μl of each elution fraction (EF) 1-6, 5μl wash (W), 5μl flow through (FT) 
and 5μl cell extract (CE) were loaded on a 10% SDS gel. The calculated size of the fusion protein is 
around 40kDa. 
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5.2.2. T4 is the only “in vitro” ATM phoshorylation site at the N-terminus of 
MDC1 
 
For the in vitro kinase assay, ATM was immunoprecipitated from HeLa nuclear 
extract by a rabbit anti human ATM polyclonal antibody, bound to Protein A-
sepharose. Immunoprecipitated ATM was incubated with either the mutant or the 
wild type GST-fusion protein. Fusion proteins were also incubated with simply kinase 
buffer as a control. The phosphorylation reaction was initiated when radioactive ATP 
was added. The reaction mix was loaded on an SDS gel. Finally, the gel was dried 
and exposed to film overnight. As expected, the wild type fragment was efficiently 
phosphorylated by ATM in vitro whereas the T4A mutant MDC1 FHA domain could 
not be phosphorylated by ATM (Figure 11; compare lane 2 and lane 4). Thus, the 
results of this in vitro ATM kinase assay provide conclusive evidence that in vitro, 
Thr4 is the only ATM phosphorylation site at the N-terminus of MDC1. 
 
 
 
 
Figure 11; The T4A fragment is not phosphorylated by ATM 
ATM was immunoprecipitated from HeLa nuclear extract. ATM resuspended in 17μl kinase buffer 
was incubated with 1μl of either the mutant or the wild type GST-fusion protein (1μg/μl). 1μl of fusion 
proteins were also incubated with simply kinase buffer as a control. The phosphorylation reaction was 
initiated when 2μl of ATP spiked with 0.5μl of 32-ATP (3000Ci/mmol) were added. The reaction mix 
was incubated for 30 minutes at 30°C before the whole amount (20μl) was loaded on a 12% SDS 
acrylamide gel. 
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5.2 Development of a tandem affinity purification (TAP) system for FHA and 
BRCT domains 
 
5.2.1 Introduction 
FHA and BRCT domains are known phosphorylation-dependent protein interaction 
modules (see introduction). However, only few bona-fide interaction partners for 
FHA and BRCT domain proteins have been identified to date. Therefore, we decided 
to search for novel interaction partners that bind to these domains in a 
phosphorylation-dependent manner in order to identify novel components of the 
DDR. To perform this biochemical screen, proteins must be exceedingly purified, so 
we set up a tandem affinity purification (TAP) system as this method was described 
in a recent published study revealing new interaction proteins of the RAD53 FHA 
domain (Smolka et al., 2006). A TAP is a two-step pull down method based on 
different short peptide tags and their corresponding affinity matrix. In contrast to the 
most frequently employed TAP system using the TEV protease for the first elution 
procedure, we have chosen a Strep-tag II that can be physiologically eluted with 
Biotin. The Strep-tag II is an eight-amino acid residue minimal peptide sequence 
consisting of Trp-Ser-His-Pro-Gln-Phe-Glu-Lys and shows intrinsic affinity toward 
Streptavidin (Schmidt and Skerra et al., 2007). The mild elution with biotin is 
replacing Strep-tag II from Streptavidine because of the higher Streptavidin binding 
affinity of Biotin. Such mild elution conditions in the first TAP purification step are 
required to assure the persistence of protein interactions. The second TAP purification 
step is using S- or Flag-tags and is designed to reach a higher purity level of the 
sample by reducing unspecific protein interactions (see Figure 12).  
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Figure 12; is a schematic illustration showing the human expression vector pEYFPnucTO with 
the subcloned BRCA1 BRCT domain including the tag triplet.  
The vector will be transfected into human U2OS cells and expressed as a fusion protein featuring 
EYFP, the BRCA1 BRCT domain and the tag triplet. In order to find novel interaction partners 
involved in the DDR, the fusion protein will be purified by TAP.  
 
The pEYFPnucTo mammalian expression vector was digested with XbaI and BamHI 
to create an empty vector. Oligonucleotides synthesized by Microsynth GMBH were 
used to insert tags into the empty vector. Oligonucleotides were designed in a way 
that the posterior XbaI restriction enzyme site was destroyed after the cloning step. 
Therefore, a new XbaI site was directly positioned behind the anterior BamHI site so 
that further inserts can be cloned into the vector using these two restriction enzymes. 
The oligonucleotides finally featured an S-tag, a central Flag-tag and a Strep-tag II 
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forming the tail of the fusion protein. As oligonucleotides are delivered as DNA 
single strands, they first needed to be annealed by passing through a descending 
temperature row (95°C for 30sec, 72°C for 2 min, 37°C for 2 min and 25°C for 
2min). Oligonucleotides annealed under formation of an anterior “sticky end” that is 
compatible with a BamHI restriction site and a posterior “sticky end” that fits into the 
XbaI site. Oligonucleotides were phosphorylated by polynucleotide kinase (PNK). 
Annealed oligonucleotides were finally ligated overnight with the empty 
pEYFPnucTO vector (pretreated with CIP) and transformed into E.coli XL1blue. This 
modified vector was used to generate all further constructs.  
In order to proof functionality of our “in vivo” pull down strategy, we decided to use 
a fragment comprising the BRCA1 BRCT domains (aa 1644-1864) as a proof-of-
principle because three interaction partners for the BRCA1-BRCT domains have 
already been identified (CtIP, BACH1, Rap80; see introduction). The BRCA1 BRCT 
domain cDNA fragment was already available in a pEYFPnuc vector. Unfortunately, 
this construct contained a terminal stop codon, so the tags would not be expressed. 
Consequently, the BRCT domains were isolated by Expand High Fidelity PCR. PCR 
success was verified by agarose gel electrophoresis. A clear band was detectable at 
the size around 650bp, indicating that the PCR reaction was successful as the 
calculated size of the BRCA1 BRCT domain amounts to 667bp (see Figure 13).  Best 
samples were purified by NucleoSpin PCR clean up.  
 
 
 
Figure 13; The BRCA1 BRCT domain was isolated by Expand High Fidelity 
5μl of the PCR reaction as well as 3μl of the 1kb marker were loaded on an agarose gel to verify PCR 
success. The BRCT domain was isolated by Expand High Fidelity PCR using the following two 
primers: BRCA1_BRCT_for (available in the lab) and BRCA1_rev_noStop (ordered from 
Microsynth). M: 1kb marker 
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The fragment as well as the vector were subsequently digested with BamHI and XbaI. 
The vector was additionally treated with CIP for one hour to prevent self-ligation. 
Again samples were loaded on an agarose gel and the relevant bands were purified by 
NucleoSpin gel extraction. Finally, the BRCA1 domain and the linearized 
pEYFPnucTo vector featuring the tags were ligated overnight and transformed into 
E.coli XL1blue cells. The plasmid was then isolated by a mini prep and subjected to a 
control digestion with BamH1 and Xba1 restriction enzymes. Unfortunately, the 
quality of the agarose gel was very bad. However, we could clearly detect the 
linearized vector at the size around 5.5kb. In order to detect a signal derived from the 
BRCA1 BRCT fragment, the exposure time had to be extremely increased. 
Consequently, the marker disappeared. However, marker bands visible at shorter 
exposure times revealed the BRCA1 BRCT fragment at its correct size around 650bp 
(see Figure 14). We sent clones Nr. 2 and 3 to Microsynth GMBH for sequencing 
(see appendix sequence report of the BRCA1 BRCT domain) 
 
 
 
Figure 14; The BRCA1 BRCT domain was successfully subcloned into the pEYFPnucTO vector 
The isolated fragment was subcloned into the empty pEYFPnucTO (featuring tags) and test digested 
with BamHI and XbaI. The marker is not visible due to the high exposure time. Clone Nr. 2 and 3 were 
sent to Microsynth GMBH for sequencing, 1.-3. samples. 
 
Proteins may interact with unspecific components of a purification system. Thus, a 
procedure where the TAP assay is carried out in parallel with the wild type protein 
and a certain point mutant that abrogates phosphorylation-specific binding should 
help to distinguish between real interaction partners and unspecific binding proteins 
(comparative pattern analysis).  
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Figure 15; Lysine at position 1702 in BRCA1 is a conserved residue within BRCT domains 
Sequence comparison of several BRCT domains from MDC1, PTIP, BANK1, BARD1, BRCA1, 
MCPH, TopBP1 and 53bp1 revealed a lysine at position 1702 in BRCA1 to be located in a highly 
conserved pattern with a crucial role for the maintenance of protein-protein interactions. The 
phosphorylation-dependent interaction is abrogated when Lys is replaced by a Met residue (Clapperton 
et al., 2004) 
 
It was shown that BRCA1 BRCT-BACH1 interaction is abrogated by the K1702M 
mutantion (Clapperton et al., 2004) (see Figure 15). The K1702M mutation in the 
BRCA1 BRCT domain was introduced by the Stratagene QuickChange Site-
Directed Mutagenesis kit. Mutation primers (for_K1702M_BRCA1 and 
rev_K1702M_BRCA1) were designed according recommendations in the Stratagene 
QuickChange Site-Directed Mutagenesis manual and synthesized by Microsynth 
GMBH. To digest the parental plasmid (pEYFPnucTo featuring tags and 
BRCA1BRCT) after the mutagenesis PCR, the mix was incubated with DPN1 that is 
specific for methylated bacterial DNA. In order to amplify the mutant plasmid, the 
PCR mix were transformed into E.coli XL1blue cells and DNA was isolated. An 
agarose gel was loaded and best results were sent to Microsynth GMBH for 
sequencing (see appendix sequence report of the K1702M mutant BRCA1 BRCT 
domain).  
Midi preps were prepared from both vectors, as transfection of cells requires a large 
amount of plasmid DNA. First we transiently transfected human 293T cells by 
calcium phosphate transfection. Unfortunately, transfection efficiency was very poor 
even though the expression level of the few transfected cells was high. The attempt to 
purify the fusion protein by a Flag-tag pull down was not successful (data not shown). 
However, since this method didn’t yield high transfection efficiency, we decided to 
generate a stable cell line expressing the tagged BRCA1-BRCT domains. Human 
osteosarcoma cell line U2OS cells were transfected according to the lipofectamin 
transfection protocol and subsequently selected by G418 antibiotic resistance. 
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Resistant clones were picked and transfection success was confirmed under the 
fluorescent microscope when the enhanced yellow fluorescent protein (EYFP) as a 
part of the fusion protein was expressed. The transfection efficiency was shown to be 
rather low and also the expression level is more or less weak. In some of transfected 
cells, nuclear dots were observable. These dots most likely represent the nucleoli (see 
Figure 16). Positive clones were transferred and cultivated in 15cm plates. The yield 
of one plate served as cell extract for one pull down experiment. Harvested cells were 
frozen in the -80°C until they were used for the pull down assays.  
 
 
     
 
Figure 16; Transfection rate and expression levels were rather low 
Human osteosarcoma U2OS cells were transfected with the pEYFPnucTO featuring the triple tagged 
BRCA1 BRCT domain. On the left side, transfected cells appear green due to the expressed EYFP. On 
the right side, nuclei of all cells shine in blue, as DAPI binds to DNA.  
 
 
5.2.2. Pull down preparations 
 
Cells were thawed on ice and resuspended in NTEN buffer. To clear the cell extract 
from insolubilized cell debris, insoluble membrane fragments and cellular matrix 
components, it was centrifuged at 14000rpm for 10 minutes. The supernatant 
containing the soluble proteins was now ready to be incubated with equilibrated 
beads.  
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5.2.3. Flag-tag pull down 
 
We first purified the fusion protein by a singlestep affinity pull downs in order to 
confirm that all tags work fine. First we tested if the Flag-tag binds to mouse Flag 
M2 agarose.  
The cell pellet was resuspended in NTEN buffer and the cleared cell extract was 
incubated with equilibrated Flag M2 agarose. Beads with bound proteins were 
washed three times with NTEN buffer. Samples were kept after each step so that the 
fusion protein could be traced through out the purification procedure. All samples 
were loaded on a gel and analyzed by silver staining as well as by Western Blotting. 
We used a polyclonal rabbit Flag antibody as primary antibody in the Western Blot.  
The calculated weight of the fusion protein is 57kDa. The Western Blot revealed a 
clear band in the eluate at the range around 60kDa, most likely representing the 
BRCT fusion protein. This strongly indicates that Flag beads are able to pull down 
and enrich the Flag-tagged fusion protein. The weak band in the supernatant (SN) 
gives further evidence that the fusion protein binds to the beads and is no longer 
present in the supernatant. Flag beads are coated with monoclonal mouse antibodies. 
After the SDS treatment these antibodies separate from the beads and solubilize in the 
eluate. When we use an mouse antibody as a secondary antibody in the Western 
Blot, two strong bands appear in the eluate representing the light and the heavy chain 
of the M2 anti flag antibody.  So we had to use the polyclonal rabbit Flag antibody 
as a primary detection reagent of our fusion protein. Polyclonal antibodies do not 
work as specifically as monoclonal antibodies, consequently four non-specific bands 
appear in the blot. However, these four bands with sizes at 200kDa, 97kDa, 70kDa 
and 30kDa are only detectable in the cell extract and in the supernatant but not in the 
eluate. There are no bands observable in none of the washing fractions indicating that 
any or only little amount of the fusion protein gets lost during the washing procedure. 
Although the antibody should have the highest affinity towards the Flag-tag, the 
fusion protein appears weaker compared to the bands at 200 and 30kDa, again 
indicating that the expression level of the fusion protein was very low in these cells 
(see Figure 17).  
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Furthermore, to test the purification specificity and in order to detect BRCA1 BRCT 
interaction partners (known or unknown), a silver stain of a Flag-tag pull down was 
performed using -Flag M2 agarose beads. The pull down was done the same way as 
for the Western Blot. The number and intensities of protein bands in the eluate reveal 
that many unspecific proteins are pulled down by the M2 Flag beads, indicating that a 
tandem purification is required to distinguish real interaction partners from unspecific 
background binding. Even though a clear band representing the fusion protein 
appeared in the Western Blot, there is no prominent band visible in the silver stain at 
around 60 kDa. This is probably due to a low expression level of the protein (see 
Figure 18).  
 
 
 
 
Figure 17; -Flag M2 agarose beads are able to pull down flag-tagged fusion proteins.  
20μl -Flag M2 agarose beads were used in the pull down. Samples were loaded on a 10% SDS gel 
and the fusion protein was detected by Western Blot using a polyclonal rabbit -Flag antibody diluted 
1:300. The film was exposed for 30 minutes and the calculated size of the fusion protein is around 
57kDa. M; low molecular weight marker, CE; Cell extract, SN; supernatant, W; washes 1-3, EL; eluate 
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Figure 18; Silver staining revealed the Flag-tag pull down as rather unspecific 
The Flag-tag pull down was performed using 30μl -Flag M2 agarose. Samples were loaded on a 10% 
SDS gel and silver stained. M; low molecular weight marker, CE; Cell extract, SN; supernatant, W; 
washes 1-3, EL; eluate 
 
 
5.2.4. GFP staining of a Flag-tag pull down 
 
Due to the structural similarity of GFP and EYFP, some antibodies against GFP also 
cross react with EYFP. As expression control we performed a Western Blot using a 
polyclonal mouse -GFP to immunostain EYFP as a part of the fusion protein. To 
this end, a Flag-tag pull down was performed and analyzed by Western Blot using the 
monoclonal -GFP antibody. A strong signal in the elutae with a molecular weight 
corresponding to our fusion protein was detected, indicating that the fusion protein is 
efficiently enriched by the Flag pull down. However, the signal in the cell extract is 
weak indicating that the fusion protein is poorly expressed (see Figure 19).  
 
 
 
 
 
 
 
 
 
Results 
52 
 
 
 
Figure 19; The fusion protein is weakly expressed but gets well enriched in the pull down 
The pull down was performed using 40μl -Flag M2 agarose beads. Samples were loaded on a 10% 
SDS gel. The monoclonal -GFP antibody used in the Western Blot was diluted 1:1000 and the film 
was exposed for 30 minutes. M; low molecular weight marker, CE; Cell extract, SN; supernatant, W; 
washes 1-3, EL; eluate 
 
5.2.5. S-tag pull downs 
 
A single step pull down was also performed using protein S agarose in order to check 
functionality of the S-tag. The pull down was done as described for the Flag-tag pull 
down. The monoclonal -Flag M2 antibody was used to detect the fusion protein by 
Western Blot. While the signal in the cell extract (CE) and also in the supernatant 
(SN) is only weak, the band representing the fusion protein in the eluate is very strong 
(see Figure 20). A closer look at the cell extract as well as at the supernatant disclose 
the fusion protein clearly appearing as a double band. The appearance of this double 
band was also observed in other pull downs (data not shown) suggesting that the 
BRCA1 BRCT domain exists in two isoforms with slightly distinct molecular weight. 
Alternatively, it is also possible that the fusion protein is partly modified, e.g. 
phosphorylated. This immunoblot also clearly demonstrated that the anti-Flag 
monoclonal antibody produced much less background than the polyclonal antibody, 
as only the band corresponding to the fusion protein can be detected. In conclusion, 
these data suggest that the S-tag works fine and the fusion protein can be efficiently 
enriched by S-protein agarose beads. Samples of a S-protein agarose pull down were 
also loaded on an SDS gel and silver stained analog to the Flag-tag pull down. The 
bands in the eluate are much weaker as compared to the Flag-tag pull down, however 
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one band at around 70kDa is clearly visible (see Figure 21). As the gel did not run 
entirely straight, this band might represent the fusion protein. However, this assay 
confirms a very low protein expression, as there is again no strong band observable in 
silver-stained SDS gels.  
 
 
 
Figure 20; S-protein agarose is able to pull down the fusion protein 
30μl S-protein agarose were used for the pull down. All samples were loaded on a 10% SDS gel. A 
monoclonal mouse -Flag M2 antibody was used in the Western Blot. The film was exposed for 1 
minute. M; low molecular weight marker, CE; Cell extract, SN; supernatant, W; washes 1-3, EL; 
eluate 
 
 
 
 
Figure 21; Silver stained SDS gel of an S-tag pull down revealed only weak bands in the eluate. 
Samples of an S-tag pull down were loaded on a 10% SDS gel and silver-stained. The pull down was 
performed using 20μl protein S agarose beads. M; low molecular weight marker, CE; Cell extract, SN; 
supernatant, W; washes 1-3, EL; eluate 
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5.2.6. Streptavidin agarose and Streptavidin dynabead pull downs 
 
To finally test the last but most important tag of the triplet, we performed a Strep-tag 
II pull down using streptavidin agarose. The pull down was again performed similar 
to the previous pull down assays. To detect the fusion protein, the monoclonal -Flag 
M2 antibody was utilized for the Western Blot. There was unfortunately no band but 
a little smear observable in the eluate. Furthermore, it seems that Strep-tag II didn’t 
bind to the streptavidin beads as the same amount of fusion protein is detected in the 
supernatant as in the cell extract (see Figure 22). The pull down was repeated several 
times in the same manner or with minor alterations but always ended up with the 
same result. A shorter exposure of the film revealed again the appearance of a double 
band in the cell extract and the supernatant. To confirm the inability of the Strep-tag 
II fusion protein to bind to streptavidin-coated beads, a further pull down was carried 
out using streptavidin dynabeads (see Figure 23). Now a clear band became visible in 
the eluate but not at the expected size, indicating that this is not our fusion protein. 
However, if the observed band is not the fusion protein, it must be another protein 
that unspecifically binds to the streptavidin-coated dynabeads and cross-reacts with 
the monoclonal -Flag antibody. As there is no band detectable in the washing 
fractions and the band appearing in the supernatant shows the same intensity as the 
band the cell extract, we have to conclude that the Strep-tag II fusion protein for some 
reason doesn’t bind efficiently to the streptavidin beads.  
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Figure 22; Streptavidin agarose beads are not able to pull down the Strep-tag II fusion protein 
40μl Streptavidin agarose beads were used in the pull down. Samples were loaded on a 10% SDS gel 
and analyzed by Western Blot. We used the monoclonal mouse -Flag M2 as primary antibody. The 
film was exposed over night. M; low molecular weight marker, CE; Cell extract, SN; supernatant, W; 
washes 1-3, EL; eluate 
 
 
 
 
Figure 23; Streptavidin dynabeads are not able to pull down the Strep-tag II fusion protein 
40μl Streptavidin dynabeads were used in the pull down. A 10% SDS gel was loaded and analyzed by 
Western Blot using the monoclonal mouse -Flag M2 antibody. Exposure time was 30 minutes. M; 
low molecular weight marker, CE; Cell extract, SN; supernatant, W; washes 1-3, EL; eluate 
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6. Discussion  
 
6.1. T4 is the only “in vitro” ATM phoshorylation site at the N-terminus of 
MDC1 
 
Our lab has recently discovered that MDC1 is phosphorylated at its N-terminus. 
Deletion of the first nine amino acids of MDC1 abrogated this phosphorylation 
(Christoph Spycher, unpublished data). There is a conserved TQ motif within the first 
nine amino acids of MDC1 and TQ motifs are known consensus ATM target sites. 
Thus, we speculated that T4 might be phosphorylated by ATM. In addition there is 
another highly conserved TQ site located at the MDC1 N-terminus: Thr98. We also 
wanted to confirm that ATM only phosphorylates Thr4 and not both Thr4 and Thr98 
In order to test this we created a GST fusion protein consisting of the first 124 amino 
acids of MDC1 and featuring the point-mutated T4A and subjected it to an “in vitro” 
ATM kinase assay. The results clearly revealed that the T4A mutant fragment was not 
phosphorylated by ATM. This indicates that ATM phosphorylates Thr4 in vitro. 
Furthermore, we can conclude that Thr4 is the only ATM phosphorylation site within 
the MDC1 N-terminus as the T4A fragment was not phosphorylated, even though 
Thr98 was still present.  
The MDC1 FHA domain spans a region between amino acids 33-131 and is 
structurally organized into a six-stranded and five-stranded -sheet forming a -
sandwich. However, Thr4 is not a component of this structural unit, so it may be 
readily accessible for phosphorylation by the ATM kinase. In contrast, Thr98 is an 
integral element of the FHA structure. The crystal structure of the MDC1 FHA 
domain has not yet been solved, but a sequence comparison between the MDC1 FHA 
domain and the RAD53 FHA domain suggests that T98 is located within or near the 
-sheet 7. This might be the reason why ATM is not able to phoshorylate Thr98, 
because the three dimensional structure allows no access for the kinase (see Figure 
24).  
FHA domains are phosphopeptide-binding domains with high specificity for 
phosphorylated threonines. Therefore, it is possible that Thr4 potentially interacts 
with such phosphopeptide-binding modules after it has been targeted by ATM in 
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response to DNA damage. No proteins have yet been identified that interact with the 
phosphorylated MDC1 N-terminal region. As MDC1 also contains an FHA domain, it 
is conceivable that MDC1 may form a homodimer in which each FHA domain binds 
to an opponent phospho-Thr4. Such a mode of interaction is currently object of 
investigations in our lab.  
 
 
 
Figure 24; is a schematic illustration about conserved residues within FHA domains 
Sequence comparisons of the MDC1 and the RAD53 FHA domains suggest that T98 is located within 
or near the -sheet 7 and can consequently not be phosphorylated by ATM because the three 
dimensional structure allows ATM no access. 
 
6.2. Development of a tandem affinity purification system for FHA and BRCT 
domains 
 
In order to identify novel components of the DDR we decided to develop a Tandem 
affinity purification (TAP) system for FHA and BRCT domains. Many proteins in the 
DDR feature FHA or BRCT domains that interact with other proteins in a 
phosphorylation-dependent manner. It is published that BRCA1 interacts with 
phosphorylated BACH1, CtIP and Rap80 through its BRCT domain (see 
introduction). So we started this project using the BRCA1 BRCT domain in order to 
test if we can retrieve any of these proteins by our “in vivo” pull down strategy. The 
fusion protein, consisting of an EYFP, BRCA1 BRCT domains and the tag triplet, 
was stably expressed in U2OS cells. To test functionality of each tag, we first tested 
each tag individually by single-step pull downs.  
In order to preserve proteins and prevent premature degradation we were using NTEN 
buffer consistent of EDTA, NaF, -glycerol-phosphate and PMSF. EDTA inhibits 
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metalloproteases by forming complexes with metal ions, which are required in the 
catalytic subunit of these enzymes. PMSF is a serine protease inhibitor and NaF stops 
glycolysis by inhibiting the enzyme enolase. -glycerol-phosphate is a phosphatase 
inhibitor. Additionally, NTEN buffer contains Nonidet P40 (NP40) a common 
nonionic detergent, used in many extraction protocols to solubilize membranes, 
especially nuclear membranes.  
Analysis of the S-and Flag-tag pull-downs by immunoblot revealed strong binding of 
the recombinant fusion protein to the affinity matrices. However, analysis of the 
Strep-tag II pull-downs showed no or only very weak binding to the Streptavidin 
beads. This indicates that even though the fusion protein is expressed, the first step of 
the TAP is highly inefficient, thus impeding the entire TAP procedure.  
When we designed our tag triplet, we had to choose between many different 
published peptide sequences that are binding to Streptavidin. To keep the tag as small 
as possible in order to avoid folding problems and to prevent any unspecific 
interactions with the rest of the protein, we have chosen the shortest tag available, the 
eight amino acid-long strep-tag II. Since the fusion protein didn’t bind to the affinity 
matrix efficiently, we concluded that the strep-tag II is not ideally suited for our 
purpose. Indeed, strep-tag II has a higher affinity to streptactin, which is a genetically 
modified Streptavidin with increased affinity to Strep-tag I and Strep-tag II (Voss et. 
al. 1997). Because of the close relations between streptactin and Streptavidin we 
would have expected much stronger binding. It can be excluded that the fusion 
protein is not expressed as it still appears in the cell extract. However, it may be that 
the expression of the fusion protein was not efficient enough, so that the affinity 
between Strep-tag II and Streptavidin was too low to enrich it in the eluate fraction. 
Interestingly though, we did detect a band in the eluate at the size around 70kDa. It is 
rather unlikely that this band corresponds to our fusion protein, because the MW of 
the protein is too high. In addition, pull downs with Flag and S-tag resins revealed the 
fusion protein in the eluate at the same position as in the cell extract, indicating that 
the fusion protein does not shift in the gel upon binding to an affinity matrix. A closer 
look at the cell extract revealed a weak band at the size around 70kDa. We suggest 
that this protein somehow unspecifically interacts with Streptavidin and thereby 
accumulates in the eluate. Unfortunately, this protein does not only seem to bind to 
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Streptavidin, but it also seems to cross-react with the monoclonal -Flag M2 antibody 
because otherwise it would not become visible on the anti-Flag immonoblot. 
Even though we could readily detect the expression of the EYFP-BCRA1-BRCT 
fusion protein by Western Blot, we were not able to identify a prominent band 
representing the fusion protein in the silver stained SDS gels of the eluate fractions. 
This indicates that the fusion protein is only weakly expressed. Nevertheless, 
numerous bands are present in the eluate, most probably representing unspecific 
binding of proteins from the cell extracts to components of the affinity matrix. 
Detection of the fusion protein in the immunoblot may be a consequence of the high 
sensitivity of the antibodies. The Western Blot analysis of a Flag-tag pull down using 
a GFP-antibody showed a very strong signal in the eluate, which is another strong 
indication that the fusion protein is indeed enriched in the eluate by the M2 beads. 
However, this strong signal should not be over-interpreted, as the primary anti GFP 
antibody in this experiment was only diluted 1:1000, whereas recommendations from 
the manufacturer propose dilutions between 1:1000 and 1:5000. The low recombinant 
protein expression level of the stably transfected U2OS cells may be the result of the 
selection procedure and several passages of the stable clones before the experiments 
were carried out. We also detected low to average expression levels by fluorescence 
microscopy. In contrast, transiently transfected cells showed higher expression levels 
under the fluorescence microscope even though in this case, only a fraction of the cell 
population expressed the fusion protein. Unfortunately, pull-down assays from 
transiently transfected cells were also not successful (data not shown). In summary, a 
key criteria to achieve readily detectable fusion proteins in pull down eluates seems to 
be stable cell lines with high expression levels of the recombinant fusion protein. 
Since our fusion protein comprises an EYFP tag, fluorescence-activated cell sorting 
(FACS) may be applied to specifically select cells with high expression levels. 
As described in the goals we originally planed to test if we could identify known 
interaction partners of the BRCA1 BRCT domains such as BACH1 or CtIP. 
However, since the first TAP step was highly inefficient, we were unable to achieve 
this goal within the given time frame. For the same reason we did not perform any 
pull down assays using the K1702M mutant. 
For TAP, an efficient first purifiation step is absolutely vital. So the next step in this 
project will be to improve the fusion construct and gear it with another streptavidin 
binding tag. A Literature search revealed the 9 amino acids long Nano-tag (9) as a 
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promising new candidate for a Strep-binding partner. The Nano-tag (9) binds to 
streptavidin with a dissociation constant of 17nM (Lamla et. al. 2004). Other 
streptavidin binding tags show similar dissociation constants (Schmidt et. al., 1993), 
(Schmidt et.al. 1996), (Keefe et.al., 2001). In conclusion, to achieve the goal to find 
new interaction partners involved in the DDR we must improve our TAP system as 
we could show that the affinity between Strep-tag II and streptavidin was too low. A 
potential candidate is the Nano-tag (9). Pull down assays using the Flag- or S-tag 
revealed efficient binding and thus, don’t need to be replaced. However, a further key 
issue is the low expression level disclosed by silver stained SDS gels from Flag- and 
S-tag pull downs. In order to increase the signal derived from the fusion protein 
versus background information we have to raise the expression level of the stably 
transfected cells. An improved selection process that specifically sorts out cells with 
high expression levels will hopefully bring success.  
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7. Abbreviations 
 
  Anti 
aa  Amino acids 
APS  Ammoniumperoxydisulfat 
ATM  Ataxia Telangiectasia Mutated 
ATP  Adenosine Triphoshpate 
ATR  ATM Related 
BACH1  BRCA1 Associated Carboxy-terminal Helicase 1 (syn. to BRIP or FancJ) 
BARD1  BRCA1 associated RING domain 1 
bp  Base pairs 
BRCA1  Breast Cancer susceptibility protein 1 
BRCT  BRCA1 Associated Carboxy-Terminus 
BSA  Bovine Serum Albumine 
Cdc25  Cell-division cycle 25 
CdK  Cycline Dependent Kinase 
CHK  Checkpoint Kinase 
CIP  Calf Intestine Phosphatase 
Crb2  Crumbs Homolog 2 
CTBP  C-terminal Binding Protein 
CtIP  CTBP interacting Protein 
DAPI  4,6-Diamidino-2-phenylindol 
DDR  DNA Damage Response 
DTT  Dithiotritol 
DNA  Desoxyribonucleic Acid 
DNA-PK DNA Dependent Kinase 
DNA-PKcs DNA-PK catalytic subunit 
dNTP  Deoxynucleotide 
ds  Double Stranded 
DSB  DNA Double-strand Break 
ECL  Enhanced Chemiluminescence 
E.coli  Escherichia Coli 
Ect2  Epithelial Cell Transforming Sequence 2 
EDTA  Ethylendimin-tetraacetic Acid 
EYFP  Enhanced Yellow Fluorescent Protein 
FCS  Fetal Calf Serum 
FHA  Forkhead Associated 
  Phosphorylated 
GFP  Green Fluorescent Protein 
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GSH  Glutathion 
GST  Glutathion S-Transferase 
H2AX  Histone 2A variant 
HEPES  4-(Hydrosyethyl) Piperazine-1-ethanesulonic Acid 
HNE  HeLa Nuclear Extract 
HR  Homologous Recombination 
IPTG  Isopropyl--thiogalactopyranoside 
IR   Ionizing Radiation 
IRIF  IR Induced Foci 
kDa  Kilo Dalton 
LB-medium Luria-Bertani-medium 
Lig 4  Ligase 4 
MDC1  Mediator of DNA Damage Checkpoint 1 
MRE11  Meiotic Recombination 11 
MRN-complex MRE11-RAD50-NBS1-complex 
NBS1  Nijmegen Breakage Syndrome 1 
NHEJ  Non-Homologues End Joining 
NLS  Nuclear Localization Signal 
NP40  Nonidet P40 
OD  Optical Density 
p53BP1  p53 Binding Protein 1 
PARP  Poly (ADP-Ribose) Polymerase 
PCR  Polymerase Chain Reaction 
PIKK  Phosphatidylinositol 3-kinase like kinases 
PMSF  Phenylmethansulfonylfluorid 
PBS  Phosphate Buffered Saline 
PNK  Polynucleotide Kinase 
RAD50  RADiation sensitive yeast 50 
RAP80  Receptor Associated Protein 80 
RNA  Ribonucleic Acid 
RNF8  Ring Finger Protein 8 
ROS  Reactive Oxygen Species 
rpm  Rounds Per Minute 
ss  Single Stranded 
SDS-PAGE Sodium Dodecyl Sulfate – Polyacrylamid Electrophoresis 
SER  Serine 
UBC13  Ubiquitin-Conjugating Enzyme 13 
TAP  Tandem Affinity Purification 
TBST  Tris-Buffered Saline Tween-20 
TEMED  N,N,N’,N’-Tetramethylethylendiamin 
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Tris  Tris-(hydrosymethyl)-aminomethan 
UV  Ultraviloet 
XRCC4  X-ray repair complementing defective repair in Chinese hamster cells 4 
 
Amino acids: 
Ala   A   Alanine 
Gln   Q   Glutamine 
Lys   K   Lysine 
Met   M   Methionine 
Ser   S   Serine 
Thr   T   Threonine 
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9. Appendix  
 
 
9.1. Buffers, Medias and Solutions 
 
Blue Dye      1ml Bromphenol blue 
       0.5ml -mercapto-ethanol (14.2M) 
       add dH2O to 10ml 
 
Buffer D      2ml Hepes (1M) 
       3.33ml KCl (3M) 
       23ml Glycerol (87%) 
       40μl EDTA (0.5M) 
       add dH2O to 100ml 
 add 0.5μl DTT (1M) to 1ml buffer 
before use 
  
Buffer E       100μl HEPES (0.5) 
       30μl NaCl (5M) 
       2μl EDTA (0.5M) 
       50μl NP40 (10%) 
       10μl PMSF (100mM) 
       1μl Leupeptin (1mg/ml) 
       1μl Pepstatin (1mg/ml) 
       1μl Bestatin (1mg/ml) 
       add dH2O to 1ml 
  
CaCl2 solution (2M)     2.22g CaCl2 
       in 10ml dH2O 
 
Destain       400ml MetOH 
       10ml Acetic Acid 
       add dH2O to 1000ml 
 
Developing solution     3g NaCO3 
50μl HCHO 
       in 100ml H2O 
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Dialysis buffer      100ml 10xTBS  
       115ml 87% Glycerol 
       add dH2O to 1000ml 
 
E1A lysis buffer       10ml ELB 
       100μl EDTA (0.5M) 
       10μl DTT (1M) 
       100μl PMSF (100mM) 
  
ELB buffer      25ml Tris (1M) 
       15ml NaCl (5M) 
       25ml NP40 (10%) 
       add dH2O to 500ml 
 
Extraction buffer      1.2ml Tris (1M, pH 6.8) 
       2.3ml Glycerol (87%) 
       2ml SDS (20%) 
       add dH2O to 10ml 
 
10x HBS      5g Hepes 
       8g NaCl 
       0.37g KCl 
       1g Dextrose 
       0.103g NaHPO4 
       add dH2O to 100ml 
 
IP buffer      3.33ml KCl (3M) 
       1ml Hepes (1M) 
       4.6ml Glycerol (87%) 
       80μl MgCl2 (1M) 
       40μl EDTA (0.5M) 
       0.4ml NaF (100mM) 
       0.4ml -glycerol-phosphat (100mM) 
       0.4ml NP40 (10%) 
       add dH2O to 40ml 
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Kinase buffer      1ml Hepes (1M) 
       0.6ml NaCl (5M) 
       80μl MnCl2 (1M) 
       120μl MgCl2 (1M) 
       2.3ml Glycerol (87%) 
       20μl DTT (1M) 
       0.2ml NaF (100mM) 
       0.2ml -glycerol-phosphat (100mM) 
       add dH2O to 20ml 
 
LB medium (Luria-Bertani medium)   10g Bactotryptone 
       5g Bacto-yeast extract 
       10g NaCl 
       in 1l dH2O 
       adjust pH to 7.0 with NaOH 
 
6x Loading buffer     30ml Glycerol (87%) 
       0.5g Bromphenol blue 
       0.5g Xylen Cynol 
       add dH2O to 200ml 
 
NTEN buffer      7.5ml NaCl (5M) 
       5ml Tris (1M, pH 7.5) 
       0.5ml EDTA (0.5M) 
       12.5ml NP40 (10% solution) 
       add dH2O to 250ml 
add just before use 
2.5ml NaF (0.1M) 
       2.5ml -glycerol-phosphat (1M) 
       1.25ml PMSF (0.2M) 
 
 
1kb Marker      30μl 1kb Marker 
       6x loading buffer 
       add dH2O to 100μl 
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PBS (Phosphat-buffered saline)    8g NaCl 
       0.2g KCl 
       1.44g Na2HPO 
       0.24g KH2PO 
       add dH2O to 1l 
       adjust pH to 7.4 with HCl 
 
Ponceau S      2g Ponceau S 
       30g Trichloridacid 
       30g Sulfatsalicyl acid 
       add dH2O to 100ml 
 
2x Running-gel buffer     150ml Tris (1M, pH 8.8) 
       2ml SDS (20%) 
       add dH2O to 200ml 
 
10x Running buffer     60.6g Tris 
       288.2g Glycin 
       add dH2O to 2l 
 
20% SDS      40g SDS 
       add dH2O to 200ml 
 
2x SDS loading buffer     1ml Tris (1M, pH 6.8) 
       50μl -mercapto ethanol 
       2ml SDS (20%) 
       200μl Bromphenol blue 
       2ml Glycerol (87%) 
 
Silver solution      0.1g AgNO3 
       in 100ml dH2O 
 
SOB       20g Bacto-Trypton 
       5g Bacto-yeast extract 
       0.5g NaCl 
       add dH2O to 1000ml 
       10ml KCl (250mM) 
       adjust pH to 7.0 with NaOH 
       5ml MgCl2 (5M) just before use 
 
Appendix 
73 
SOB++       1l SOB 
       10ml MgSO4 just before use 
 
SOC       980ml SOB 
       20ml Glucose (1M) 
 
Solution A      5g Na2CO3 
       1g NaOH 
       add dH2O to 250ml 
 
Solution B      50mg CuSO4(5H2O) 
       0.1g Sodium citrate  
       add dH2O to 10ml 
 
Stacking-gel buffer     30.2ml Tris (1M, pH6.8) 
       1.2ml SDS (20%) 
       100μl Bromphenol blue 
       add dH2O to 200ml 
     
Stain       0.25g Coomassie Brilliant Blue R250 
       100ml MeOH 
       25ml Acetic acid  
       add dH2O to 250ml  
 
Stripping buffer      1.25ml Tris (1M, pH 6.8) 
       1.6ml SDS (20%) 
       140μl -mercapto-ethanol 
       add dH2O to 20ml 
 
1x TAE buffer      4.84g Tris 
       1.14g Gluacal acetic acid 
       2ml EDTA (0.5M, pH8) 
       add dH2O to 1000ml 
 
TB buffer      5ml Hepes (0.5M, pH 6.7) 
       3.75ml CaCl2 (1M) 
       25ml KCl (2.5M) 
       add dH2O to 250ml 
       adjust pH to 6.7 with KOH 
       add 27.5ml MnCl2 (0.5M) before use 
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1x TBS buffer      12.1g Tris 
       87.7g NaCl 
       add dH2O to 1000ml 
 
TBS-T       1l TBS 
       0.5ml Tween 20 
 
Transfer buffer      100ml Running buffer (10%) 
       200ml Methanol 
       add dH2O to 1l 
 
 
9.2. Primers and Oligonucleotides 
 
53bp1_BRCT_for 
5’-CGC GGA TCC TTG CCT CTC AAC AAG ACC-3’ 
 
53bp1_BRCT_rev 
5’-CGC TCT AGA GTG AGA AAC ATA ATC GTG-3’ 
 
53bp1_BRCT_for_K1814M 
5’-CAG CAT TGT CGA ACC CGG ATG TAC TTC CTG TGC CTT GCC-3’ 
 
53BP1_BRCT_rev_K1814M 
5’-GGC AAG GCA CAG GAA GTA CAT CCG GGT TCG ACA ATG CTG-3’ 
 
BRCA1_BRCT_for 
5’-CGC GGA TCC GAA AGG GTC AAC AAA AGA A-3’ 
 
BRCA1_BRCT_rev 
5’-GCT CTA GAT CAG TAG TGG CTG TGG GGG-3’ 
 
BRCA1_rev_noStop 
5’-GCT CTA GAG TAG TGG CTG TGG GGG ATC TGG-3’ 
 
for_K1702M_BRCA1 
5’-GTG TGT GAA CGG ACA CTG ATG TAT TTT CTA GGA ATT GCG G-3’ 
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rev_K1702M_BRCA1 
5’-CCG CAA TTC CTA GAA AAT ACA TCA GTG TCC GTT CAC ACA C-3’ 
 
for_Tags_03.12.08 
5’-GAT CCG CGT CTA GAA AAG AAA CCG CTG CTG CGA AAT TTG AAC GCC AGC ACA 
TGG ACT CGG CGG ACT ACA AAG ACG ATG ACG ACA AGG CGG ATG TTG AAG CTT 
GGC TTG ACG AAC GTG-3’ 
 
rev_Tags_03.12.08 
5’-CTA GCA CGT TCG TCA AGC CAA GCT TCA ACA TCC GCC TTG TCG TCA TCG TCT 
TTG TAG TCC GCC GAG TCC ATG TGC TGG CGT TCA AAT TTC GCA GCA GCG GTT TCT 
TTT CTA GAC GCG-3’ 
 
M-1 T4A_fw 
5’- CTG GAT CCA TGG AGG ACG CCC AGG CTA TTG ACT GGG ATG -3’ 
 
M_FHA_rev 
5’- GCT CTA GAC TGT ACT CTG GGT GTC TCT TCT ACT G -3’ 
 
MDC1_BRCT_for 
5’-CGC GGA TCC GCA GAG GAG GAG CCC AAC AG-3’ 
 
MDC1_BRCT_rev 
5’-CGC TCT AGA GGT GGA TGA CAT CTC CAA AG-3’ 
 
S-Flag-Strep-for 
5’-GAT CCG CGT CTA GAA AAG AAA CCG CTG CTG CGA AAT TTG AAC GCC AGC ACA 
TGG ACT CGG CGG ACT ACA AAG ACG ATG ACG ACA AGG CGT GGA GCC ACC CGC 
AGT TCG AAA AAG-3’ 
 
S-Flag-Strep-rev 
5’-CTA GCT TTT TCG AAC TGC GGG TGG CTC CAC GCC TTG TCG TCA TCG TCT TTG 
TAG TCC GCC GAG TCC ATG TGC TGG CGT TCA AAT TTC GCA GCA GCG GTT TCT TTT 
CTA GAC GCG-3’ 
 
T4Agex-for 
5’-GTG GAT CCA TGG AGG ACG CCC AGG CTA TTG ATCT GG-3’ 
 
T4Agex_rev 
5’-CCA GTC AAT AGC CTG GGC GTC CTC CAT GGA TCC AC-3’ 
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9.3 Sequencing Results 
 
 
 
 
Sequence report of the T4A mutant N-terminal fragment of MDC1 
 
 
 
 
 
 
Sequence Report of the BRCA1 BRCT domain 
 
 
 
 
 
 
Appendix 
77 
 
 
 
Sequence Report of the K1702M mutant BRCA1 BRCT domain 
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